STOCK TITAN

Biotricity flags going-concern doubt as losses widen

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Biotricity Inc. (BTCY) reported revenue of $8,611,403 for the six months ended September 30, 2026, compared with $7,759,788 a year earlier. Net loss attributable to common stockholders was $2,024,351 versus $1,526,616; net cash generated in operating activities was $510,748 versus $42,241.

At September 30, 2026, cash was $268,998 and the working capital deficiency was $32,293,286. Biotricity was in default under term-loan covenants and related subordination requirements. The lender agreed to forbear from exercising remedies through December 31, 2026, subject to earlier termination if a forbearance default occurs. Refinancing was not finalized, and management said its plans did not alleviate substantial doubt about the company’s ability to continue as a going concern.

The May 2026 exchanges involved 2,009,197 Series C preferred shares in return for common shares, options and warrants. Each Series C share carries 40 votes. Upon a qualified equity financing with gross proceeds of at least $15 million, the shares automatically convert into common shares representing 59.6% of outstanding common shares after giving effect to shares issued or issuable in the financing. If no qualified financing occurs by March 31, 2028, holders may convert each Series C share into 10 common shares.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

4 major · 4 points

How the balance works

Positive

  • Moderate point$8,611,403 six-month revenue, versus $7,759,788 a year earlier.
  • Moderate point$510,748 net cash generated in operating activities, versus $42,241 in the prior-year period.

Negative

  • Major point$2,024,351 net loss attributable to common stockholders, versus $1,526,616.
  • Major point$32,293,286 working capital deficiency as of September 30, 2026.
  • Major pointTerm-loan covenant and subordination defaults remain under forbearance through December 31, 2026.
  • Major pointManagement said its plans did not alleviate substantial doubt about Biotricity’s ability to continue as a going concern.

Filing Explained

At September 30, 2026, 2,854,504 Series B conversion shares remained due, adding potential common-share dilution beyond the 21,792,165 common and exchangeable shares then outstanding.

This quarterly report says Biotricity had 2,854,504 common shares from Series B conversions recorded as still to be issued at September 30, 2026, in addition to 21,792,165 common and exchangeable shares then outstanding, and issuing the pending shares would increase the share count and reduce existing holders’ percentage ownership.

The company also reports that 494,231 of the 2,009,197 Series C shares tied to the May exchanges remained to be issued at quarter-end, pending transfer-agent registration formalities.

Under the term-loan arrangement, the company is making payments of about $55,000 a week through December 31, 2026; the lender may apply them to interest, fees, past-due amounts or principal, but had not applied them to principal to date.

If the company has not made at least $5 million in aggregate principal repayments by December 31, 2026, principal payments of $1.2 million become due on each payment date beginning in February 2027. If refinancing is not completed by December 31, 2026, the company must issue the lender warrants for 100,000 common shares, plus 100,000 more for each 30 days until completion.

Six-month revenue $8,611,403 Six months ended September 30, 2026; $7,759,788 for the same period in 2025
Net loss attributable to common stockholders $2,024,351 Six months ended September 30, 2026; $1,526,616 for the same period in 2025
Net cash generated in operating activities $510,748 Six months ended September 30, 2026; $42,241 for the same period in 2025
Cash $268,998 As of September 30, 2026
Working capital deficiency $32,293,286 As of September 30, 2026
Term loan balance including exit fee $15,270,932 As of September 30, 2026
Series C preferred shares issued and issuable 2,009,197 shares In connection with exchanges during the six months ended September 30, 2026
Common shares upon qualified-financing conversion 59.6% Series C preferred shares automatically convert upon a qualified equity financing with gross proceeds of at least $15 million
substantial doubt financial
"conditions raise substantial doubt about its ability to continue as a going concern"
forbearance agreement financial
"The term lender has agreed to forbear from exercising its rights and remedies"
A forbearance agreement is a temporary deal between a borrower and a lender where the lender agrees to delay or reduce payments instead of declaring a default; think of it as a pause button on a loan while both sides work out a longer-term fix. It matters to investors because it affects a company’s short-term cash flow and the likelihood of loan losses or restructuring, which can change credit risk and share value.
working capital deficiency financial
"had a working capital deficiency of $32,293,286"
Working capital deficiency occurs when a company's short-term resources—cash, inventory and money owed to it—are less than its short-term obligations like bills, wages and debt coming due. Like a household that has more monthly bills than money in the bank, this situation signals a liquidity squeeze that may force borrowing, asset sales or cuts to dividends, and it matters to investors because it raises the risk of operational disruption and reduced shareholder returns.
mezzanine equity financial
"The Series B Preferred Stock should be classified as mezzanine equity"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
performance obligations financial
"recognize the deferred revenue when the applicable performance obligations are satisfied"
Performance obligations are the specific promises a company makes to deliver goods or services to a customer under a contract, treated as separate deliverables when a customer can benefit from them on their own. Investors care because these promises determine when and how much revenue a company records — like breaking a bundled purchase into separate billable parts — which affects reported earnings, growth trends and the clarity of future cash flows.
qualified equity financing financial
"completion of a qualified equity financing resulting in gross proceeds of at least $15 million"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did BTCY report for the six months ended September 30, 2026?

BTCY reported $8,611,403 in revenue for the six months ended September 30, 2026, compared with $7,759,788 for the same period in 2025.

Why did BTCY report substantial doubt about continuing as a going concern?

Biotricity reported recurring operating losses, a $32,293,286 working capital deficiency and defaults under its term loan. Refinancing and planned financing had not been finalized, and management concluded that its plans did not alleviate substantial doubt about the company’s ability to continue as a going concern for one year from issuance of the interim financial statements.

How could BTCY’s Series C preferred shares convert?

A qualified equity financing with gross proceeds of at least $15 million triggers automatic conversion into common shares representing 59.6% of outstanding common shares after giving effect to shares issued or issuable in that financing. If no qualified financing occurs by March 31, 2028, holders may convert each Series C share into 10 common shares.

What are the payment terms for BTCY’s term loan?

Through December 31, 2026, Biotricity makes payments of approximately $55,000 per week, which the lender may apply to interest, fees, past-due amounts or principal. If aggregate principal repayments of at least $5.0 million have not been made by December 31, 2026, $1,200,000 principal repayments are due on each payment date beginning in February 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q2 2027 --03-31 0001630113 0001630113 2026-04-01 2026-09-30 0001630113 2026-11-16 0001630113 2026-09-30 0001630113 2026-03-31 0001630113 BTCY:PreferredStocksMember 2026-09-30 0001630113 BTCY:PreferredStocksMember 2026-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 us-gaap:SeriesCPreferredStockMember 2026-09-30 0001630113 us-gaap:SeriesCPreferredStockMember 2026-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-03-31 0001630113 2025-04-01 2025-09-30 0001630113 2026-07-01 2026-09-30 0001630113 2025-07-01 2025-09-30 0001630113 us-gaap:PreferredStockMember 2026-06-30 0001630113 us-gaap:CommonStockMember 2026-06-30 0001630113 BTCY:SharesToBeIssuedMember 2026-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001630113 us-gaap:RetainedEarningsMember 2026-06-30 0001630113 2026-06-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-06-30 0001630113 BTCY:MezzanineEquityMember 2026-06-30 0001630113 us-gaap:PreferredStockMember 2026-03-31 0001630113 us-gaap:CommonStockMember 2026-03-31 0001630113 BTCY:SharesToBeIssuedMember 2026-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001630113 us-gaap:RetainedEarningsMember 2026-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-03-31 0001630113 BTCY:MezzanineEquityMember 2026-03-31 0001630113 us-gaap:PreferredStockMember 2025-06-30 0001630113 us-gaap:CommonStockMember 2025-06-30 0001630113 BTCY:SharesToBeIssuedMember 2025-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001630113 us-gaap:RetainedEarningsMember 2025-06-30 0001630113 2025-06-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-06-30 0001630113 BTCY:MezzanineEquityMember 2025-06-30 0001630113 us-gaap:PreferredStockMember 2025-03-31 0001630113 us-gaap:CommonStockMember 2025-03-31 0001630113 BTCY:SharesToBeIssuedMember 2025-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001630113 us-gaap:RetainedEarningsMember 2025-03-31 0001630113 2025-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-03-31 0001630113 BTCY:MezzanineEquityMember 2025-03-31 0001630113 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001630113 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001630113 BTCY:SharesToBeIssuedMember 2026-07-01 2026-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001630113 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-07-01 2026-09-30 0001630113 BTCY:MezzanineEquityMember 2026-07-01 2026-09-30 0001630113 us-gaap:PreferredStockMember 2026-04-01 2026-09-30 0001630113 us-gaap:CommonStockMember 2026-04-01 2026-09-30 0001630113 BTCY:SharesToBeIssuedMember 2026-04-01 2026-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-09-30 0001630113 us-gaap:RetainedEarningsMember 2026-04-01 2026-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-04-01 2026-09-30 0001630113 BTCY:MezzanineEquityMember 2026-04-01 2026-09-30 0001630113 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001630113 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001630113 BTCY:SharesToBeIssuedMember 2025-07-01 2025-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001630113 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-07-01 2025-09-30 0001630113 BTCY:MezzanineEquityMember 2025-07-01 2025-09-30 0001630113 us-gaap:PreferredStockMember 2025-04-01 2025-09-30 0001630113 us-gaap:CommonStockMember 2025-04-01 2025-09-30 0001630113 BTCY:SharesToBeIssuedMember 2025-04-01 2025-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-09-30 0001630113 us-gaap:RetainedEarningsMember 2025-04-01 2025-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-04-01 2025-09-30 0001630113 BTCY:MezzanineEquityMember 2025-04-01 2025-09-30 0001630113 us-gaap:PreferredStockMember 2026-09-30 0001630113 us-gaap:CommonStockMember 2026-09-30 0001630113 BTCY:SharesToBeIssuedMember 2026-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001630113 us-gaap:RetainedEarningsMember 2026-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2026-09-30 0001630113 BTCY:MezzanineEquityMember 2026-09-30 0001630113 us-gaap:PreferredStockMember 2025-09-30 0001630113 us-gaap:CommonStockMember 2025-09-30 0001630113 BTCY:SharesToBeIssuedMember 2025-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001630113 us-gaap:RetainedEarningsMember 2025-09-30 0001630113 2025-09-30 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-09-30 0001630113 BTCY:MezzanineEquityMember 2025-09-30 0001630113 BTCY:TechnologyFeesMember 2026-07-01 2026-09-30 0001630113 BTCY:TechnologyFeesMember 2025-07-01 2025-09-30 0001630113 BTCY:TechnologyFeesMember 2026-04-01 2026-09-30 0001630113 BTCY:TechnologyFeesMember 2025-04-01 2025-09-30 0001630113 BTCY:DeviceSalesMember 2026-07-01 2026-09-30 0001630113 BTCY:DeviceSalesMember 2025-07-01 2025-09-30 0001630113 BTCY:DeviceSalesMember 2026-04-01 2026-09-30 0001630113 BTCY:DeviceSalesMember 2025-04-01 2025-09-30 0001630113 BTCY:OneToThirtyDaysMember 2026-09-30 0001630113 BTCY:OneToThirtyDaysMember 2026-03-31 0001630113 BTCY:ThirtyOneToSixtyDaysMember 2026-09-30 0001630113 BTCY:ThirtyOneToSixtyDaysMember 2026-03-31 0001630113 BTCY:SixtyOneToNinetyDaysMember 2026-09-30 0001630113 BTCY:SixtyOneToNinetyDaysMember 2026-03-31 0001630113 BTCY:NinetyOneToOneEigthyDaysMember 2026-09-30 0001630113 BTCY:NinetyOneToOneEigthyDaysMember 2026-03-31 0001630113 BTCY:OneEigthyDaysOrMoreMember 2026-09-30 0001630113 BTCY:OneEigthyDaysOrMoreMember 2026-03-31 0001630113 2025-04-01 2026-03-31 0001630113 BTCY:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-09-30 0001630113 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001630113 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001630113 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001630113 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001630113 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001630113 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001630113 us-gaap:OfficeEquipmentMember 2026-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001630113 BTCY:DevicePurchaseandLicensingAgreementMember 2026-07-01 2026-09-30 0001630113 BTCY:DevicePurchaseandLicensingAgreementMember 2026-09-30 0001630113 BTCY:DevicePurchaseandLicensingAgreementMember 2026-04-01 2026-09-30 0001630113 BTCY:SeriesANoteMember 2026-09-30 0001630113 BTCY:SeriesANoteMember 2026-03-31 0001630113 BTCY:SeriesANoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:SeriesANoteMember 2025-03-31 0001630113 BTCY:SeriesANoteMember 2025-04-01 2026-03-31 0001630113 BTCY:SeriesANoteMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesANoteMember 2026-07-01 2026-09-30 0001630113 BTCY:SeriesANoteMember 2026-04-01 2026-09-30 0001630113 BTCY:SeriesANoteMember 2025-07-01 2025-09-30 0001630113 BTCY:SeriesANoteMember 2025-04-01 2025-09-30 0001630113 BTCY:SeriesBNoteMember 2026-09-30 0001630113 BTCY:SeriesBNoteMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesBNoteMember 2026-03-31 0001630113 BTCY:SeriesBNoteMember 2025-03-31 0001630113 BTCY:SeriesBNoteMember 2025-04-01 2026-03-31 0001630113 BTCY:SeriesBNoteMember 2026-07-01 2026-09-30 0001630113 BTCY:SeriesBNoteMember 2026-04-01 2026-09-30 0001630113 BTCY:SeriesBNoteMember 2025-07-01 2025-09-30 0001630113 BTCY:SeriesBNoteMember 2025-04-01 2025-09-30 0001630113 BTCY:SeriesCNoteMember 2026-09-30 0001630113 BTCY:SeriesCNoteMember 2026-07-01 2026-09-30 0001630113 BTCY:SeriesCNoteMember 2025-04-01 2026-03-31 0001630113 BTCY:SeriesCNoteMember 2025-09-30 0001630113 BTCY:SeriesCNoteMember 2025-04-01 2025-09-30 0001630113 BTCY:SeriesCNoteMember 2026-03-31 0001630113 BTCY:SeriesCNoteMember 2026-04-01 2026-09-30 0001630113 BTCY:SeriesCNotesMember 2026-07-01 2026-09-30 0001630113 BTCY:SeriesCNotesMember 2026-04-01 2026-09-30 0001630113 BTCY:SeriesCNotesMember 2025-07-01 2025-09-30 0001630113 BTCY:SeriesCNotesMember 2025-04-01 2025-09-30 0001630113 srt:MinimumMember 2026-09-30 0001630113 srt:MaximumMember 2026-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-09-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2025-03-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 2023-10-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2025-04-01 2026-03-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2026-09-30 0001630113 BTCY:EighteenMonthAnniversaryMember 2026-03-31 0001630113 2024-01-31 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-31 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2026-09-30 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2026-03-31 0001630113 2024-04-01 2025-03-31 0001630113 BTCY:SixMonthAnniversaryMember 2024-04-01 2025-03-31 0001630113 BTCY:SixMonthAnniversaryMember 2025-03-31 0001630113 BTCY:TwelveMonthAnniversaryMember 2024-04-01 2025-03-31 0001630113 BTCY:TwelveMonthAnniversaryMember 2025-03-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-04-01 2025-03-31 0001630113 BTCY:UnsecuredConvertiblePromissoryNotesMember 2025-04-01 2026-03-31 0001630113 BTCY:NineMonthAnniversaryMember 2026-03-31 0001630113 BTCY:NineMonthAnniversaryMember 2025-04-01 2026-03-31 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2025-04-01 2026-03-31 0001630113 BTCY:TwentyFourMonthOneAnniversaryMember 2025-04-01 2026-03-31 0001630113 BTCY:TwentyFourMonthOneAnniversaryMember 2026-03-31 0001630113 BTCY:TwentyFourMonthTwoAnniversaryMember 2025-04-01 2026-03-31 0001630113 BTCY:TwentyFourMonthTwoAnniversaryMember 2026-03-31 0001630113 BTCY:UnsecuredConvertiblePromissoryNotesMember 2026-03-31 0001630113 BTCY:UnsecuredConvertiblePromissoryNotesMember 2026-04-01 2026-09-30 0001630113 BTCY:NineMonthAnniversaryMember 2026-09-30 0001630113 BTCY:ConvertibleNoteMember 2026-09-30 0001630113 BTCY:ConvertibleNoteMember 2026-03-31 0001630113 BTCY:ConvertibleNoteMember 2026-07-01 2026-09-30 0001630113 BTCY:ConvertibleNoteMember 2026-04-01 2026-09-30 0001630113 BTCY:ConvertibleNoteMember 2025-07-01 2025-09-30 0001630113 BTCY:ConvertibleNoteMember 2025-04-01 2025-09-30 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2026-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2026-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2026-04-01 2026-09-30 0001630113 BTCY:NewPromissoryNoteMember 2026-09-30 0001630113 BTCY:NewPromissoryNoteMember 2026-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2026-09-30 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2026-03-31 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2026-09-30 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2026-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2026-09-30 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2026-03-31 0001630113 BTCY:SepteberTwoThousandTwentySixMember 2026-09-30 0001630113 BTCY:SepteberTwoThousandTwentySixMember 2026-03-31 0001630113 BTCY:ShortTermMember 2026-09-30 0001630113 BTCY:ShortTermMember 2026-03-31 0001630113 BTCY:ShortTermMember 2026-07-01 2026-09-30 0001630113 BTCY:ShortTermMember 2026-04-01 2026-09-30 0001630113 BTCY:ShortTermMember 2025-07-01 2025-09-30 0001630113 BTCY:ShortTermMember 2025-04-01 2025-09-30 0001630113 2021-12-21 0001630113 2021-12-21 2021-12-21 0001630113 2024-11-01 2024-11-30 0001630113 2024-11-30 0001630113 BTCY:ForbearanceAgreementMember 2025-12-31 0001630113 BTCY:WarrantAgreementMember 2025-12-31 0001630113 2025-12-31 0001630113 BTCY:ForbearanceAgreementMember 2025-12-31 2025-12-31 0001630113 BTCY:CreditAgreementMember 2025-04-01 2026-03-31 0001630113 BTCY:CreditAgreementMember 2026-09-30 0001630113 BTCY:CreditAgreementMember 2026-03-31 0001630113 BTCY:CreditAgreementMember 2026-07-01 2026-09-30 0001630113 BTCY:CreditAgreementMember 2026-04-01 2026-09-30 0001630113 BTCY:CreditAgreementMember 2025-07-01 2025-09-30 0001630113 BTCY:CreditAgreementMember 2025-04-01 2025-09-30 0001630113 BTCY:CreditAgreementMember 2025-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-01 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-05-01 2021-05-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2026-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2026-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2026-07-01 2026-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2026-04-01 2026-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2025-07-01 2025-09-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2025-04-01 2025-09-30 0001630113 us-gaap:SeriesAPreferredStockMember 2026-04-01 2026-09-30 0001630113 us-gaap:ConvertibleDebtMember 2026-04-01 2026-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2026-04-01 2026-09-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2026-04-01 2026-09-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2025-04-01 2026-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:SeriesAPreferredStockMember 2025-04-01 2026-03-31 0001630113 srt:MinimumMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 srt:MaximumMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001630113 srt:MinimumMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 srt:MaximumMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001630113 us-gaap:ConvertibleDebtMember 2026-03-31 0001630113 us-gaap:ConvertibleDebtMember 2025-03-31 0001630113 us-gaap:ConvertibleDebtMember 2025-04-01 2026-03-31 0001630113 us-gaap:ConvertibleDebtMember 2026-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2026-04-01 2026-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2026-04-01 2026-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2025-04-01 2026-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2025-04-01 2026-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2026-09-30 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2026-09-30 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2026-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2026-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-09-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2025-09-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2025-03-31 0001630113 us-gaap:SeriesAPreferredStockMember BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-09-30 0001630113 us-gaap:SeriesAPreferredStockMember BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-03-31 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-09-30 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-03-31 0001630113 us-gaap:SeriesCPreferredStockMember BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-09-30 0001630113 us-gaap:SeriesCPreferredStockMember BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2026-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001630113 BTCY:SeriesBConvertiblePreferredStockMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2024-04-01 2025-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-04-01 2024-03-31 0001630113 2023-04-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-19 0001630113 BTCY:PurchaseAgreementMember us-gaap:SeriesBPreferredStockMember 2023-09-18 2023-09-19 0001630113 BTCY:SharesToBeIssuedOrCancelledMember 2026-07-01 2026-09-30 0001630113 BTCY:SharesToBeIssuedOrCancelledMember 2026-04-01 2026-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2026-04-01 2026-09-30 0001630113 us-gaap:SeriesBPreferredStockMember 2025-09-30 0001630113 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember BTCY:ExchangeAgreementsMember 2026-05-01 2026-05-01 0001630113 us-gaap:CommonStockMember BTCY:ExchangeSharesAgreementMember 2026-05-01 2026-05-01 0001630113 us-gaap:CommonStockMember BTCY:ExchangeOptionsAgreementMember 2026-05-01 2026-05-01 0001630113 us-gaap:CommonStockMember BTCY:ExchangeWarrantsAgreementMember 2026-05-01 2026-05-01 0001630113 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember BTCY:ExchangeAgreementsMember 2026-05-22 2026-05-22 0001630113 us-gaap:CommonStockMember BTCY:ExchangeSharesAgreementMember 2026-05-22 2026-05-22 0001630113 us-gaap:CommonStockMember BTCY:ExchangeOptionsAgreementMember 2026-05-22 2026-05-22 0001630113 us-gaap:CommonStockMember BTCY:ExchangeOptionsAgreementMember us-gaap:SeriesCPreferredStockMember 2026-04-01 2026-09-30 0001630113 us-gaap:SeriesCPreferredStockMember 2026-05-22 0001630113 us-gaap:SeriesBPreferredStockMember 2025-04-01 2026-03-31 0001630113 us-gaap:CommonStockMember 2026-08-31 2026-08-31 0001630113 us-gaap:SeriesBPreferredStockMember 2026-08-31 2026-08-31 0001630113 us-gaap:SeriesBPreferredStockMember 2025-07-01 2025-09-30 0001630113 BTCY:SharesToBeIssuedOrCancelledMember us-gaap:SeriesCPreferredStockMember 2026-04-01 2026-09-30 0001630113 us-gaap:CommonStockMember BTCY:ExchangeWarrantsAgreementMember 2026-07-01 2026-09-30 0001630113 srt:OfficerMember BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember us-gaap:WarrantMember 2026-05-22 2026-05-22 0001630113 2026-05-22 2026-05-22 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember 2023-03-31 0001630113 us-gaap:CommonStockMember BTCY:ExchangeOptionsAgreementMember 2026-04-01 2026-09-30 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember us-gaap:WarrantMember 2026-05-22 2026-05-22 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember 2026-05-22 2026-05-22 0001630113 us-gaap:SeriesBPreferredStockMember 2025-03-31 0001630113 BTCY:BrokerWarrantsMember 2026-03-31 0001630113 BTCY:ConsultantAndNoteholderWarrantsMember 2026-03-31 0001630113 BTCY:WarrantsIssuedOnConvertibleNotesMember 2026-03-31 0001630113 BTCY:BrokerWarrantsMember 2026-04-01 2026-09-30 0001630113 BTCY:ConsultantAndNoteholderWarrantsMember 2026-04-01 2026-09-30 0001630113 BTCY:WarrantsIssuedOnConvertibleNotesMember 2026-04-01 2026-09-30 0001630113 BTCY:BrokerWarrantsMember 2026-09-30 0001630113 BTCY:ConsultantAndNoteholderWarrantsMember 2026-09-30 0001630113 BTCY:WarrantsIssuedOnConvertibleNotesMember 2026-09-30 0001630113 BTCY:BrokerWarrantsMember srt:MinimumMember 2026-09-30 0001630113 BTCY:BrokerWarrantsMember srt:MaximumMember 2026-09-30 0001630113 BTCY:NewLeaseAgreementMember 2021-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpense 2026-04-01 2026-09-30 0001630113 us-gaap:SellingGeneralAndAdministrativeExpense 2025-04-01 2025-09-30 0001630113 2022-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001630113 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001630113 us-gaap:OfficeEquipmentMember 2025-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001630113 us-gaap:OfficeEquipmentMember 2025-04-01 2026-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2025-04-01 2026-03-31 0001630113 us-gaap:OfficeEquipmentMember 2026-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001630113 us-gaap:OfficeEquipmentMember 2026-04-01 2026-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2026-04-01 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure BTCY:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the quarterly period ended September 30, 2026
   
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the period from ______________ to_______________

 

Commission file number: 001-40761

 

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

 

Nevada   30-0983531
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065 and 75 International Blvd., Suite 300, Toronto, ON, Canada

(Address of principal executive offices)

 

(800) 590-4155

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act).

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 21,631,493 shares of Common Stock, $0.001 par value, at November 16, 2026. As at that same date, the Company also has 160,672 Exchangeable Shares outstanding that convert directly into common shares, which when combined with its Common Stock produce an amount equivalent to 21,792,165 outstanding voting securities.

 

 

 

 

 

 

BIOTRICITY INC.

 

Part I – Financial Information 3
   
Item 1 – Condensed Consolidated Interim Financial Statements 3
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations 37
Item 3 – Quantitative and Qualitative Disclosures About Market Risk 48
Item 4 – Controls and Procedures 48
   
Part II – Other Information 49
   
Item 1 – Legal Proceedings 49
Item 1A – Risk Factors 49
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 49
Item 3 – Defaults Upon Senior Securities 49
Item 4 – Mine Safety Disclosures 49
Item 5 – Other Information 49
Item 6 – Exhibits 49
Signatures 50

 

2

 

 

PART 1

 

FINANCIAL INFORMATION

 

Item 1 – Condensed Consolidated Interim Financial Statements

 

Condensed Consolidated Interim Balance Sheets at September 30, 2026 (unaudited) and March 31, 2026 (audited) 4
   
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the three and six months ended September 30, 2026 and 2025 (unaudited) 5
   
Condensed Consolidated Interim Statements of Mezzanine Equity and Stockholders’ Deficiency for the three and six months ended September 30, 2026 and 2025 (unaudited) 6
   
Condensed Consolidated Interim Statements of Cash Flows for the six months ended September 30, 2026 and 2025 (unaudited) 10
   
Notes to the Condensed Consolidated Interim Financial Statements 11

 

3

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

AS OF SEPTEMBER 30, 2026 (unaudited) AND MARCH 31, 2026 (audited)

(Expressed in US Dollars, unless otherwise noted)

 

    As at
September 30, 2026
    As at
March 31, 2026
 
    $     $  
CURRENT ASSETS                
Cash     268,998       149,789  
Accounts receivable, net     2,553,571       2,932,899  
Inventory [Note 3]     1,284,813       1,341,295  
Deposits and other receivables     1,748,023       1,432,501  
Total current assets     5,855,405       5,856,484  
                 
Deposits and other receivables     112,322       109,297  
Long-term accounts receivable     60,321       130,847  
Property and equipment [Note 12]     669       3,646  
Operating right of use assets [Note 10]     89,403       346,214  
TOTAL ASSETS     6,118,120       6,446,488  
                 
CURRENT LIABILITIES                
Accounts payable and accrued liabilities [Note 4]     10,271,911       8,970,870  
Convertible promissory notes and short term loans [Note 5]     10,792,793       11,114,209  
Term loan, current     14,992,380       14,680,914  
Derivative liabilities [Note 8]     457,770       445,893  
Advance from customers     1,531,530       1,531,530  
Operating lease obligations, current [Note 10]     102,307       397,830  
Total current liabilities     38,148,691       37,141,246  
                 
Federally guaranteed loans [Note 7]     870,800       870,800  
Derivative liabilities [Note 8]     1,527,635       1,396,908  
TOTAL LIABILITIES     40,547,126       39,408,954  
                 
Mezzanine Equity                
Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of September 30, 2026 and March 31, 2026, respectively, 310 and 335 shares issued and outstanding as of September 30, 2026 and March 31, 2026, respectively [Note 9]     1,560,391       1,714,476  
                 
STOCKHOLDERS’ EQUITY (DEFICIENCY)                
Preferred stock, $0.001 par value, 7,879,400 and 9,979,400 shares authorized as of September 30, 2026 and March 31, 2026, respectively, 1 share issued and outstanding as of September 30, 2026 and March 31, 2026 [Note 9]     1       1  
Preferred stock, $0.001 par value, 20,000 authorized as at September 30, 2026 and March 31, 2026, respectively, 201 and 201 preferred shares issued and outstanding as at September 30, 2026 and as at March 31, 2026, respectively [Note 9]     —       —  
Series C Preferred Stock, $2.35 and $0.001 par value, 2,100,000 and - Nil shares authorized as at September 30, 2026 and March 31, 2026, respectively, 2,009,197 and 0 Nil preferred shares issued and issuable as at September 30, 2026 and March 31, 2026, [Note 9]     2,433,002       —  
Common stock, $0.001 par value, 125,000,000 authorized as at September 30, 2026 and March 31, 2026, respectively.
Issued and outstanding common shares: 21,631,493 and 28,597,315 as at September 30, 2026 and March 31, 2026, respectively, and exchangeable shares of 160,672 outstanding as at September 30, 2026 and March 31, 2026, respectively [Note 9]
    21,794       28,759  
Shares to be cancelled 1,379,963 and to be issued 1,005,815 shares of common stock as at September 30, 2026 and March 31, 2026, respectively [Note 9]     282,283       284,668  
Additional paid-in-capital     105,912,136       107,621,813  
Accumulated other comprehensive loss     (44,019 )     (41,940 )
Accumulated deficit     (144,594,594 )     (142,570,243 )
Total stockholders’ equity (deficiency)     (35,989,397 )     (34,676,942 )
TOTAL LIABILITIES, MEZZANINE AND STOCKHOLDERS’ DEFICIENCY     6,118,120       6,446,488  

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

4

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (unaudited)

(Expressed in US Dollars)

 

   6 Months Ended September 30, 2026   6 Months Ended September 30, 2025   3 Months Ended September 30, 2026   3 Months Ended September 30, 2025 
   $   $   $   $ 
                 
REVENUE   8,611,403    7,759,788    4,334,447    3,885,795 
                     
Cost of Revenue   1,471,869    1,461,490    725,733    704,297 
GROSS PROFIT   7,139,534    6,298,298    3,608,714    3,181,498 
                     
EXPENSES                    
Selling, general and administrative expenses   5,084,806    4,443,573    2,385,498    2,304,881 
Research and development expenses   1,557,945    1,298,961    884,501    602,798 
TOTAL OPERATING EXPENSES   6,642,751    5,742,534    3,269,999    2,907,679 
INCOME FROM OPERATIONS   496,783    555,764    338,715    273,819 
                     
Other income [Note 3]   76,442    173,270    35,538    106,599 
Interest expense   (1,705,834)   (1,710,673)   (854,081)   (860,419)
Gain upon convertible promissory notes conversion and redemption [Note 8]   —    8,433    —    — 
Accretion and amortization expenses   (373,509)   (355,713)   (176,873)   (202,141)
Change in fair value of derivative liabilities [Note 8]   (261,511)   (33,971)   (151,460)   (8,771)
NET LOSS BEFORE INCOME TAXES   (1,767,629)   (1,362,890)   (808,161)   (690,913)
                     
Income taxes   —    —    —    — 
NET LOSS BEFORE DIVIDENDS   (1,767,629)   (1,362,890)   (808,161)   (690,913)
                     
Preferred Stock Dividends   (256,722)   (163,726)   (145,880)   (81,410)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS   (2,024,351)   (1,526,616)   (954,041)   (772,323)
                     
Translation adjustment   (2,079)   (26,883)   (4,548)   9,286 
                     
COMPREHENSIVE LOSS   (2,026,430)   (1,553,499)   (958,589)   (763,037)
                   
LOSS PER SHARE, BASIC AND DILUTED   (0.092)   (0.057)   (0.046)   (0.029)
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING   21,917,420    26,767,370    20,751,281    26,767,370 

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

5

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY

FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (unaudited)

 

   Shares   $   $   Shares   $   Shares   $   Shares   $   $   $   $   $ 
   Mezzanine
Equity
   Total
Mezzanine
Equity
   Preferred
stock
   Common stock
and exchangeable
common shares
   Shares to be
Issued
   Additional
paid in
capital
   Accumulated
other
comprehensive
(loss) income
   Accumulated
deficit
   Total
Stockholders’
Deficiency
 
   Shares   $   $   Shares   $   Shares   $   Shares   $   $   $   $   $ 
Balance, June 30, 2026   335    1,714,476    1,714,476    2,009,398    2,433,003    20,235,347    20,237    (4,234,467)   279,428    105,542,543    (41,518)   (143,640,553)   (35,406,860)
Conversion of mezzanine equity into common shares [Note 9]   (25)   (154,084)   (154,084)    -          1,500,000    1,500    2,854,504    2,855    363,514              367,869 
Issuance of shares for services [Note 9]                            56,818    57              6,080              6,136 
Translation adjustment                                                     (2,501)        (2,501)
Net loss before dividends for the period                        -                                  (808,161)   (808,161)
Preferred stock dividends                                                          (145,880)   (145,880)
Balance, September 30, 2026   310    1,560,391    1,560,391    2,009,398    2,433,003    21,792,165    21,794    (1,379,963)   282,283    105,912,136    (44,019)   (144,594,594)   (35,989,397)

 

6

 

 

   Mezzanine
Equity
   Total
Mezzanine
Equity
   Preferred
stock
   Common stock
and exchangeable
common shares
   Shares to be
Issued
   Additional
paid in
capital
   Accumulated
other
comprehensive
(loss) income
   Accumulated
deficit
   Total
Stockholders’
Deficiency
 
   Shares   $   $   Shares   $   Shares   $   Shares   $   $   $   $   $ 
Balance, March 31, 2026   335    1,714,476    1,714,476    201    1    28,757,987    28,759    1,005,815    284,668    107,621,813    (41,940)   (142,570,243)   (34,676,942)
Conversion of mezzanine equity into common shares [Note 9]   (25)   (154,084)   (154,084)   —    —    2,305,619    2,306    2,430,288    2,431    363,132    —    —    367,869 
Exchange of common shares, warrants and options into Preferred C Shares   —    —    —    2,009,197    2,433,002    (9,328,259)   (9,328)   (4,816,066)   (4,816)   (2,418,858)   —    —    — 
Issuance of shares for services [Note 9]   —    —    —    —    —    56,818    57    —    —    6,080    —    —    6,136 
Stock based compensation - ESOP [Note 9]   —    —    —    —    —    —    —    —    —    339,970    —    —    339,970 
Translation adjustment   —    —    —    —    —    —    —    —    —    —    (2,079)   —    (2,079)
Net loss before dividends for the period   —    —    —    —    —    —    —    —    —    —    —    (1,767,629)   (1,767,629)
Preferred stock dividends   —    —    —    —    —    —    —    —    —    —    —    (256,722)   (256,722)
Balance, September 30, 2026   310    1,560,391    1,560,391    2,009,398    2,433,003    21,792,165    21,794    (1,379,963)   282,283    105,912,136    (44,019)   (144,594,594)   (35,989,397)

 

7

 

 

    Shares     $     $     Shares     $     Shares     $     Shares     $     $     $     $     $  
    Mezzanine
Equity
    Total
Mezzanine
Equity
    Preferred
stock
    Common stock
and
exchangeable
common shares
    Shares to be
Issued
    Additional
paid in
capital
    Accumulated
other

comprehensive
(loss) income
    Accumulated
deficit
    Total
Stockholders’
Deficiency
 
    Shares     $     $     Shares     $     Shares     $     Shares     $     $     $     $     $  
Balance, June 30, 2025     385       2,000,290       2,000,290       201       1       26,728,441       26,729       581,599       284,244       107,128,749       (42,562 )     (140,196,078 )     (32,798,917 )
Conversion of mezzanine equity into common shares [Note 9]     (25 )     (250,000 )     (250,000 )     —       —       223,839       224       —       —       143,351       —       —       143,575  
Stock based compensation - ESOP [Note 9]     —       —       —       —       —       —       —       —       —       6,001       —       —       6,001  
Translation adjustment     —       —       —       —       —       —       —       —       —       —       9,286       —       9,286  
Net loss before dividends for the period     —       —       —       —       —       —       —       —       —       —       —       (690,913 )     (690,913 )
Preferred stock dividends     —       —       —       —       —       —       —       —       —       —       —       (81,410 )     (81,410 )
Balance, September 30, 2025     360       1,750,290       1,750,290       201       1       26,952,280       26,953       581,599       284,244       107,278,101       (33,276 )     (140,968,401 )     (33,412,378 )

 

8

 

 

    Mezzanine Equity    

Total

Mezzanine

Equity

   

Preferred

  stock

   

Common stock

and exchangeable

common shares

   

Shares to be

Issued

   

Additional

paid in capital

   

Accumulated

other

comprehensive

(loss) income

   

Accumulated

  deficit

   

Total

Stockholders’

Deficiency

 
    Shares     $     $     Shares     $     Shares     $     Shares     $     $     $     $     $  
Balance, March 31, 2025     385       2,000,290       2,000,290       201       1       26,241,967       26,243       581,599       284,244       107,123,300       (6,393 )     (139,441,785 )     (32,014,390 )
Conversion of mezzanine equity into common shares [Note 9]     (25 )     (250,000 )     (250,000 )     —       —       710,313       710       —       —       142,865       —       —       143,575  
Stock based compensation - ESOP [Note 9]     —       —       —       —       —       —       —       —       —       11,936       —       —       11,936  
Translation adjustment     —       —       —       —       —       —       —       —       —       —       (26,883 )     —       (26,883 )
Net loss before dividends for the period     —       —       —       —       —       —       —       —       —       —       —       (1,362,890 )     (1,362,890 )
Preferred stock dividends     —       —       —       —       —       —       —       —       —       —       —       (163,726 )     (163,726 )
Balance, September 30, 2025     360       1,750,290       1,750,290       201       1       26,952,280       26,953       581,599       284,244       107,278,101       (33,276 )     (140,968,401 )     (33,412,378 )

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

9

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (UNAUDITED)

(Expressed in US Dollars)

 

   Six Months Ended
September 30, 2026
   Six Months ended
September 30, 2025
 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss   (1,767,629)   (1,362,890)
Adjustments to reconcile net loss to net cash used in operations          
Stock based compensation   339,970    11,936 
Issuance of shares for services   6,136    

—

 
Accretion and amortization expenses   373,509    355,713 
Change in fair value of derivative liabilities   261,511    33,971 
Loss (Gain) on debt and share conversion and redemption   —    (8,433)
Property, plant and equipment depreciation   2,977    2,977 
Non cash lease expense   256,811    225,373 
           
Changes in operating assets and liabilities:   —      
Accounts receivable, net   449,853    (453,519)
Inventory   56,482    (700,904)
Deposits and other receivables   (318,547)   187,570 
Advance from Customers   —    1,895,920 
Accounts payable and accrued liabilities   849,675    (145,473)
Net cash generated in operating activities   510,748    42,241 
           
CASH FLOWS FROM INVESTING ACTIVITIES          
           
property, plant and equipment   —    — 
Net cash used in investing activities   —    — 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Issuance of common shares, net   —    — 
Issuance of preferred shares, net   —    — 
Conversion of preferred shares   —    — 
Redemption of preferred shares   —    (200,000)
Conversion of convertible notes   —    — 
Exercise of warrants for cash   —    — 
Issuance of warrants to brokers   —    — 
Issuance of warrants for private placement holders   —    — 
Issuance of warrants for services   —    — 
Federally guaranteed loans   —    — 
Proceeds from (repayment to) convertible debentures, net   —    — 
Proceeds from (repayment to) short term loan and promissory notes, net   (383,460)   739,990 
Issuance of shares from uplisting   —    — 
Due to shareholders   —    — 
Term Loan, net   —    (600,000)
Preferred Stock Dividend   (6,000)   (12,033)
Net cash used in financing activities   (389,460)   (72,043)
           
Effect of foreign currency translation   (2,079)   (26,883)
Net increase (decrease) in cash during the period   121,288    (29,802)
Cash, beginning of period   149,789    365,145 
Cash, end of period   268,998    308,460 
Supplemental disclosure of cash flow information:          
Cash paid for interest   1,431,201    1,683,697 

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

10

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

1. NATURE OF OPERATIONS

 

Biotricity Inc. (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.

 

The Company (directly and through its subsidiary) is engaged in research and development activities within the remote monitoring segment of preventative care. Its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.

 

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

 

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements and should be read in conjunction with Biotricity’s audited consolidated financial statements for the years ended March 31, 2026 and 2025 and their accompanying notes.

 

The accompanying unaudited condensed consolidated interim financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending March 31, 2027. The Company’s fiscal year-end is March 31.

 

The unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated.

 

Reclassifications

 

Certain amounts presented in the prior year period have been reclassified to conform to current period consolidated interim financial statement presentation.

 

Going Concern, Liquidity and Basis of Presentation

 

The accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern. The Company is commercializing its first product ecosystem and is concurrently continuing in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of September 30, 2026, had an accumulated deficit of $144,594,594 (March 31, 2026 – $142,570,243) and a working capital deficiency of $32,293,286 (March 31, 2026 – $31,284,762), and the Company is in default under its term loan, which is subject to a forbearance agreement through December 31, 2026 (see Note 6). Those conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance of these condensed consolidated interim financial statements. The condensed consolidated interim financial statements do not include adjustments that might result from the outcome of this uncertainty.

 

Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and additional equity and debt capitalization of the Company.

 

11

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures.

 

Management’s plans to address these conditions include continued growth in recurring technology fee revenue, maintaining positive income from operations and cash flows from operating activities, obtaining additional equity or debt financing, and refinancing the Company’s term loan prior to its maturity. The Company’s term lender has agreed to forbear from exercising its rights and remedies through December 31, 2026, and management expects to obtain further forbearance beyond that date pending the refinancing of the term loan (see Note 6). Management believes that, if successfully implemented, these plans would provide sufficient liquidity to fund the Company’s operations for at least the next twelve months. However, because the completion of the planned financings and the refinancing of the term loan are not within the Company’s control and had not been finalized as of the date these condensed consolidated interim financial statements were issued, management has concluded that its plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the following core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied.

 

Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.

 

The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business.

 

12

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

The Company recognized the following forms of revenue for the three and six months ended September 30, 2026, and 2025:

 

   2026   2025   2026   2025 
  

Three months ended

September 30

  

Six months ended

September 30

 
   2026   2025   2026   2025 
   $   $   $   $ 
Technology fees   3,979,178    3,511,454    8,145,579    6,882,846 
Device sales   355,268    374,341    465,823    876,942 
Revenue recognized   4,334,447    3,885,795    8,611,403    7,759,788 

 

Inventories

 

Inventory is stated at the lower of cost and net realizable value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.

 

    September 30, 2026     March 31, 2026  
    $     $  
Raw material     768,587       768,587  
Finished goods     516,226       572,708  
                 
Inventories     1,284,813       1,341,295  

 

Accounts Receivable - Net

 

Accounts Receivable

 

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for expected credit losses to estimate the amount of receivables that may not be collected. The allowance is determined using a current expected credit loss (“CECL”) methodology that incorporates historical loss experience, current economic conditions, aging of receivable balances, customer-specific risk characteristics and reasonable and supportable forecasts.

 

The Company evaluates receivables collectively based on similar risk characteristics, including customer payment history, aging status, customer significance and other relevant factors. Receivables deemed uncollectible are written off against the allowance when collection efforts have been exhausted. Recoveries of amounts previously written off are recorded when received.

 

13

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

Accounts receivable consisted of the following:

 

    September 30, 2026     March 31, 2026  
    $     $  
Gross Accounts Receivable   $ 1,743,163     $ 1,911,354  
Other Receivables     898,178       1,092,371  
                 
Gross Receivables   $ 2,641,341       3,003,725  
Provision     (87,770 )     (70,826 )
Balance end of quarter   $ 2,553,571     $ 2,932,899  

 

Accounts receivable primarily consist of amounts due from medical facilities, government programs, and patients arising from the Company’s normal course of business.

 

Other receivables primarily consist of accrued receivables related to device sales embedded in all-inclusive arrangements, unbilled sales, accrued technology fees, receivables from third parties,

 

Accounts Receivable Aging

 

The aging analysis below relates only to trade accounts receivable and excludes other receivables.

 

    September 30, 2026     March 31, 2026  
Current   $ 1,270,607     $ 11,813  
31-60 days     128,565       852,359  
61-90 days     78,469       686,298  
91-180 days     147,107       329,511  
180 days or more     118,416       31,372  
                 
Total   $ 1,743,163     $ 1,911,354  

 

Allowance for Expected Credit Losses

 

Changes in the allowance for expected credit losses for the quarter ended September 30, 2026 and March 31, 2026 were as follows:

 

   September 30, 2026   March 31, 2026 
   $   $ 
Balance beginning of year   70,826    70,860 
Write - offs   (12,456)   (74,780)
Recoveries   -    60,000 
Provision during the Period   29,400    14,746 
           
Balance end of quarter   87,770    70,826 

 

14

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

Significant accounting estimates and assumptions

 

The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors we consider reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

 

Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities:

 

● Fair value of stock options

 

The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.

 

● Fair value of warrants

 

In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.

 

● Fair value of derivative liabilities

 

In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.

 

● Functional currency

 

Determining the appropriate functional currencies for entities that comprise the consolidated Company requires analysis of various factors, including the currencies and country-specific factors that influence labor, materials, and other operating expenses.

 

15

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

● Useful life of property and equipment

 

The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.

 

● Provisions

 

Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.

 

● Contingencies

 

Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.

 

● Inventory obsolescence

 

Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.

 

● Income and other taxes

 

The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses.

 

16

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated interim balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated.

 

● Incremental borrowing rate for lease

 

The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated interim financial statements.

 

Earnings (Loss) Per Share

 

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.

 

Advance from Customers

 

The Company receives advance payments from customers primarily for the sale of its medical devices. These advances represent consideration received prior to the transfer of control of the goods to the customer and are recorded as Advances from Customers on the balance sheet. These advances are unsecured, non-interest bearing, and have no specific terms or conditions attached.

 

Cash

 

Cash includes cash on hand and balances with banks.

 

As of September 30, 2026 and March 31, 2026, cash balances of $268,998 and $149,789 respectively, were at financial institutions in the United States that were not covered by the United States Deposit Protection Regulation.

 

17

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

Foreign Currency Translation

 

The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated interim balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, consolidated interim balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these condensed consolidated interim financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

 

Accounts Receivable

 

Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated interim balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that we believe to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

 

Customer Concentration

 

For the six months ended September 30, 2025, the Company had a significant customer concentration, with one customer accounting for approximately 23% of total revenue. For the six months ended September 30, 2026, no individual customer accounted for 10% or more of total revenue.

 

Fair Value of Financial Instruments

 

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

 

● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

 

● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

 

● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

 

18

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

 

The fair value of financial instruments measured on a recurring basis is as follows:

 

   As of September 30, 2026 
Description  Total   Level 1   Level 2   Level 3 
Assets:                    
Total assets at fair value  $—   $—   $—   $— 
                     
Liabilities:                    
Derivative liabilities, short-term  $457,770   $—   $—   $457,770 
Derivative liabilities, long-term   1,527,635    —    —    1,527,635 
Total liabilities at fair value  $1,985,405   $—   $—   $1,952,852 

 

   As of March 31, 2026 
Description  Total   Level 1   Level 2   Level 3 
Assets:                    
Total assets at fair value  $—   $—   $—   $— 
                     
Liabilities:                    
Derivative liabilities, short-term  $445,893   $—   $—   $445,893 
Derivative liabilities, long-term   1,396,908    —    —    1,396,908 
Total liabilities at fair value  $1,842,801   $—   $—   $1,842,801 

 

There were no transfers between fair value hierarchy levels during the six months ended September 30, 2026, and 2025.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow:

 

Office equipment   5 years
Leasehold improvement   5 years

 

19

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

Impairment for Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at September 30, 2026 and March 31, 2026, the Company believes there was no impairment of its long-lived assets.

 

Leases

 

The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated interim balance sheet.

 

Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated interim balance sheet and are expensed on a straight-line basis over the lease term in the consolidated interim statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated interim financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.

 

Research and Development

 

Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.

 

20

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

Selling, General and Administrative

 

Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.

 

Stock Based Compensation

 

The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated interim statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

Convertible Notes Payable and Derivative Instruments

 

The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated interim balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

 

Series B Convertible Preferred Stock

 

The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated interim statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815.

 

21

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

Preferred Shares Extinguishments

 

The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss.

 

Segment Information

 

Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of September 30, 2026 and 2025.

 

The CODM uses net loss for purposes of making operating decisions, allocating resources, and evaluating financial performance. Significant expenses include non-cash stock-based compensation, depreciation and amortization, and write-off of property and equipment, which are reflected in the Consolidated interim Statements of Cash Flows.

 

The long-lived assets outside of U.S. are not material as of September 30, 2026. The measure of segment assets is reported on the balance sheet as total consolidated assets. Refer to the Consolidated Interim Balance Sheets as of September 30, 2026 and 2025 for total consolidated assets.

 

Recently Issued Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which clarifies the accounting for certain settlements of convertible debt instruments. The Company adopted ASU 2024-04 effective April 1, 2026. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient related to estimating expected credit losses on certain current accounts receivable and contract assets. The Company adopted ASU 2025-05 effective April 1, 2026. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

 

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

   As at
September 30, 2026
   As at
March 31, 2026
 
   $   $ 
Trade and other payables   4,923,872    4,402,523 
Accrued liabilities   4,824,371    4,534,809 
Deferred revenue   618,545    33,538 
Total   10,271,911    8,970,870 

 

Trade and other payables and accrued liabilities as at September 30, 2026 and March 31, 2026 included $1,229,862 and $1,053,228, respectively, due to a shareholder, who is a director and executive of the Company.

 

During the three months ended September 30, 2026, the Company received $585,000 pursuant to a device purchase and licensing agreement involving certain medical devices.

 

Under the agreement, the Company retains the exclusive rights to possess, use, deploy and control the devices throughout their useful lives. The agreement also provides for revenue-sharing arrangements based on collections generated from the devices.

 

As of September 30, 2026, the devices had not been manufactured, and the Company had not satisfied the related performance obligations. Accordingly, the Company recorded the $585,000 received as deferred revenue in the accompanying condensed consolidated balance sheets. No revenue was recognized in connection with this arrangement during the three and six months ended September 30, 2026.

 

The Company will recognize the deferred revenue when the applicable performance obligations are satisfied and the revenue recognition criteria under ASC 606 are met.

 

22

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS

 

Series A Convertible Promissory Notes:

 

The Company’s Series A Convertible Promissory Notes bear interest at 12% per annum and are convertible into common shares pursuant to the terms of the respective notes.

 

As of September 30, 2026, notes held by two investors remained outstanding with an aggregate principal balance of $821,500 (March 31, 2026 – $821,500). During prior years, substantially all Series A Notes were converted into common shares, with the exception of these remaining notes.

 

On December 30, 2022, the Company exchanged $500,000 of Series A Notes together with accrued interest of $121,500 for a new convertible note with principal of $621,500. The replacement note bears interest at 12% per annum and is convertible into common shares at a price equal to 75% of the average of the three lowest closing prices during the ten trading days preceding receipt of a conversion notice.

 

As of March 31, 2026 and March 31, 2025, accrued interest related to the Series A Notes was $370,922 and $272,342, respectively.

 

During the years ended March 31, 2026 and 2025, the Company recognized interest expense of $98,580 and $98,580, respectively.

 

As of September 30, 2026 and March 31, 2026, accrued interest related to the Series A Notes was $420,347 and $370,922, respectively.

 

During the three and six months ended September 30, 2026, the Company recognized interest expense of $24,848 and $49,425, respectively, on Series A convertible notes. During the three and six months ended September 30, 2025, the Company recognized interest expense of $24,848 and $49,425, respectively, on Series A convertible notes.

 

The discount associated with the Series A Notes was fully amortized in prior years.

 

Series B Convertible Notes

 

The Company previously issued Series B Convertible Promissory Notes that bore interest at 12% per annum and were convertible into shares of the Company’s common stock pursuant to the terms of the notes.

 

During the year ended March 31, 2025, the Company redeemed the remaining principal balance of $22,009 through a cash payment of $25,342. As a result of the redemption, the Company recognized a gain on redemption of $8,320 during the year ended March 31, 2025.

 

As of March 31, 2026 and March 31, 2025, there was no outstanding principal balance related to the Series B Convertible Promissory Notes.

 

As of March 31, 2026 and March 31, 2025, accrued interest related to the Series B Convertible Promissory Notes was $88,881 and $88,881, respectively.

 

During the years ended March 31, 2026 and 2025, the Company recognized interest expense of $nil and $279, respectively.

 

23

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

As of September 30, 2026 and March 31, 2026, accrued interest related to the Series B Convertible Promissory Notes was $88,881 and $88,881, respectively.

 

During the three and six months ended September 30, 2026, the Company recognized interest expense of $nil and $nil, respectively. During the three and six months ended September 30, 2025, the Company recognized interest expense of $nil and $nil, respectively.

 

Series C Convertible Notes

 

The Company’s Series C Convertible Promissory Notes bear interest at 15% per annum and are convertible into shares of the Company’s common stock pursuant to the terms of the applicable notes.

 

As of September 30, 2026, one Series C Note remained outstanding with an aggregate principal balance of $116,667 (March 31, 2026 – $116,667). The remaining note continues to be subject to the original conversion provisions of the applicable note agreement.

 

During the six months ended September 30, 2026, there were no redemptions of Series C Notes. During the six months ended September 30, 2025, Series C Notes with a face value of $25,000 and accrued interest of $6,826 were redeemed for a cash payment of $31,826, resulting in a gain on redemption of $8,433.

 

During the three and six months ended September 30, 2026 and 2025, there were no conversions of Series C Notes into common stock.

 

As of September 30, 2026 and March 31, 2026, accrued interest related to the Series C Notes was $58,236 and $49,340, respectively.

 

During the three and six months ended September 30, 2026, the Company recognized interest expense of $4,472 and $8,896, respectively. During the three and six months ended September 30, 2025, the Company had no interest expense, as prior period accruals were adjusted following the June 2025 debt redemption.

 

During the three and six months ended September 30, 2026 and 2025, the Company recognized no accretion or amortization expense related to the Series C Notes, as all debt discounts had been fully amortized as of March 31, 2025.

 

24

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

During the three and six months ended September 30, 2026, the Company recognized interest expense of $4,472 and $8,896, respectively. During the three and six months ended September 30, 2025, the Company had no interest expense, as prior period accruals were adjusted following the June 2025 debt redemption.

 

Convertible Preferred Notes

 

The Company has issued unsecured preferred notes and convertible promissory notes to private investors. Certain notes bear fixed interest rates ranging from 8% to 20% per annum and contain conversion features that require the mutual consent of the investor and the Company. As the conversion features are not solely within the control of the holder, the Company has not recognized derivative liabilities related to these conversion options.

 

The Company entered into a convertible preferred note financing on September 25, 2023 and issued a Preferred Note with a principal amount of $1,000,000. The Preferred Note bears interest at a fixed rate of 12% per annum, payable in cash monthly.

 

As of March 31, 2025, the outstanding principal balance of the Preferred Note was $1,000,000. During the year ended March 31, 2026, the Company made principal repayments in accordance with the terms of the note, and as of March 31, 2026, the Preferred Note had been fully repaid with no balance remaining outstanding.

 

The Company also issued a Preferred Note on October 25, 2023 in the principal amount of $250,000, bearing interest at a fixed rate of 12% per annum, payable in cash quarterly. During the year ended March 31, 2026, the Company repaid $100,000 of the principal balance in accordance with the terms of the note. As of September 30, 2026, the outstanding principal balance was $150,000 (March 31, 2026 – $150,000)

 

The Company issued a further Preferred Note in January 2024 for a principal amount of $114,303, bearing interest at a fixed rate of 8% per annum, payable in cash quarterly. As of September 30, 2026, the outstanding principal balance remained $114,303 (March 31, 2026 – $114,303).

 

During the year ended March 31, 2025, the Company issued $1,985,000 in unsecured convertible promissory notes to private investors; $100,000 of the notes matured on their six-month anniversary of issuance and bore interest at 20% per annum; $710,000 of the notes mature on their twenty-four month anniversary of issuance and bear interest at 10% per annum; and $1,175,000 of the notes mature on their eighteen-month anniversary of issuance and bear no interest. All of the notes contain conversion features that require the mutual consent of the investor and the Company, and as the conversion is not solely within the control of the holder, the Company did not recognize a derivative liability in connection with these conversion options. During the year ended March 31, 2026, the Company repaid in full the $100,000 note that matured on its six-month anniversary of issuance, together with all accrued interest thereon, the outstanding principal balance remained $1,885,000 as of September 30, 2026 (March 31, 2026 – $1,885,000).

 

During the year ended March 31, 2026, the Company issued $1,395,000 in unsecured convertible promissory notes to private investors. The notes bear interest at rates ranging from 10% to 12% per annum and mature between nine and twenty-four months from issuance. Specifically, $65,000 of the notes mature on their nine-month anniversary and bear interest at 10% per annum; $500,000 mature on their twenty-four month anniversary and bear interest at 12% per annum; $730,000 mature on their twenty-four month anniversary and bear interest at 10% per annum; and $100,000 mature on their twenty-four month anniversary and bear interest at 10.5% per annum. The Company received gross proceeds of $1,395,000 from these issuances. In connection with the financings, the Company incurred financing fees of $46,500, resulting in net proceeds of $1,348,500. An additional $50,000 in unsecured convertible promissory notes were issued to private investors during the six months ended September 30, 2026. These notes mature on their twenty four-month anniversary of issuance and bear interest at 10% per annum. As the conversion features of these notes are not solely within the control of the holder, the Company did not recognize a derivative liability associated with the conversion options. As of September 30, 2026, the aggregate outstanding principal balance of these notes was $1,445,000 (March 31, 2026 - $1,395,000).

 

25

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

The financing fees were capitalized as deferred financing costs and are presented as a reduction of the related debt balances in the consolidated balance sheet in accordance with ASC 835-30 and ASC 470-10. These costs are amortized over the contractual terms of the respective notes using a method that approximates the effective interest method. During the six months ended September 30, 2026 Company recognized amortization expense of $11,444 related to these deferred financing costs (Year ended March 2026 – $17,973).

 

As of September 30, 2026 and March 31, 2026, accrued interest related to the Preferred Notes and convertible promissory notes was $106,789 and $56,309, respectively.

 

During the three and six months ended September 30, 2026, the Company recognized interest expense of $68,091 and $146,330, respectively. During the three and six months ended September 30, 2025, the Company recognized interest expense of $57,031 and $109,272, respectively.

 

Other Convertible Notes

 

On January 23, 2023, the Company issued a convertible preferred note with a principal amount of $2,000,000 to an accredited investor. The note bears interest at a fixed rate of 10% per annum and contains conversion features that become effective upon a qualified financing or upon mutual agreement of the Company and the noteholder. As the conversion feature is not solely within the control of the holder, the Company has not recognized a derivative liability related to the conversion option.

 

As of March 31, 2026 and March 31, 2025, the discount associated with the note was fully amortized.

 

As of September 30, 2026 and March 31, 2026, the outstanding principal balance of the note was $2,000,000 and $2,000,000.

 

Other Short-term loans and Promissory Notes

 

The Company maintains various debt arrangements, including promissory notes, a revolving financing facility, bridge loans and other financing arrangements.

 

As of September 30, 2026, the Company had the following principal balances outstanding:

 

  ● A promissory note issued in December 2022 with principal outstanding of $600,000 (March 31, 2026 – $600,000) bearing interest at 25% per annum.
  ● A promissory note issued in December 2022 in connection with the extinguishment of warrants, with principal outstanding of $270,000 (March 31, 2026 – $270,000).
  ● A revolving accounts receivable and inventory financing facility with aggregate principal outstanding of $1,714,149 (March 31, 2026 – $2,108,109).
  ● A promissory note issued in February 2024, including subsequent advances, with principal outstanding of $1,263,768 (March 31, 2026 – $1,263,768)
  ● An unsecured loan issued in July 2025 with principal outstanding of $250,000 (March 31, 2026 – $250,000).
  ● A short-term bridge loan entered into during December 2025 with principal outstanding of $72,520 (March 31, 2026 – $177,226)
  ● A short-term loan raised in Sep 2026 with principal outstanding of $100,000 (March 31, 2026 - $nil)

 

As of September 30, 2026, accrued interest related to these arrangements totaled $392,563 (March 31, 2026 – $311,033).

 

26

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

During the three and six months ended September 30, 2026, the Company recognized interest expense of $199,542 and $420,620, respectively related to these debt arrangements, During the three and six months ended September 30, 2025, the Company recognized interest expense of $204,009 and $382,769, respectively. The interest expense included the financing costs, accretion and facility charges. Deferred financing costs are recorded as a reduction of the related debt balances and amortized over the contractual terms of the respective arrangements.

 

6. TERM LOAN AND CREDIT AGREEMENT

 

Term Loan

 

On December 21, 2021, the Company entered into a Credit Agreement (as amended, the “Credit Agreement”) with SWK Funding LLC (“SWK”), pursuant to which the Company borrowed approximately $12.4 million. Runway Growth Finance Corp. (“Runway” or the “Lender”), as successor to SWK by way of merger, acts as agent and a lender under the Credit Agreement. The term loan is secured by substantially all of the Company’s assets, including certain intellectual property. As amended, the term loan matures on May 15, 2027 and bears interest at the three-month Term SOFR rate, subject to a 1.0% floor, plus 10.5% per annum, payable monthly in cash.

 

Through December 31, 2026, the Company makes payments to the Lender of approximately $55,000 per week, which the Lender may apply to interest, fees, past-due amounts or principal. To date, the Lender has not applied these payments to principal. If the Company has not made aggregate principal repayments of at least $5.0 million by December 31, 2026, principal repayments of $1,200,000 are due on each payment date beginning in February 2027, with the balance due at maturity. Accordingly, the outstanding balance of the term loan is classified as a current liability as of September 30, 2026 and March 31, 2026.

 

An exit fee of $1,425,000 is payable on repayment of the term loan and is included in the outstanding balance below. An additional fee equal to 2% of the highest principal amount outstanding becomes payable if the term loan remains outstanding after December 31, 2026.

 

In November 2024, the Company entered into an amendment with the Lender pursuant to which it received additional term loan proceeds of approximately $635,000 and capitalized approximately $1.5 million of accrued interest into the outstanding principal balance. In connection with this amendment, the Company issued 600,000 warrants exercisable at $0.50 per share and agreed to increase the exit fee payable upon maturity of the facility. The Company also received waiver and forbearance relief relating to certain covenant defaults.

 

In December 2025, the Company entered into an additional forbearance agreement with the Lender and issued 120,000 warrants exercisable at $0.37 per share. Additionally, the Company issued 27,150 warrants exercisable at $2.21 per share in accordance with the terms of a previously executed warrant agreement. The warrants had an aggregate fair value of $38,078 and were recorded as additional debt discount.

 

The Company is in default under certain provisions of the Credit Agreement, including its minimum liquidity, minimum revenue and minimum EBITDA covenants and requirements relating to the subordination of other indebtedness (the “specified defaults”). Since September 2025, the Company and the Lender have entered into a series of forbearance agreements, the most recent of which is dated June 30, 2026. Under the current forbearance agreement, the Lender has agreed not to exercise its rights and remedies in respect of the specified defaults, including acceleration of the term loan, until December 31, 2026, or earlier if a forbearance default occurs. Among other things, the Company must meet specified milestones toward a refinancing of the term loan by December 31, 2026. It may not make cash payments on its preferred stock or, until subordination agreements are in place, its subordinated debt without the Lender’s consent. The Lender may appoint a non-voting observer to the Company’s Board. If the refinancing is not completed by December 31, 2026, the Company must issue the Lender warrants to purchase 100,000 shares of common stock, plus 100,000 more for each 30 days until it is completed. The Company has also agreed to register for resale the shares issuable on exercise of warrants held by the Lender. The Lender has made no commitment to extend the forbearance period. The Company is pursuing a refinancing and expects to obtain further forbearance beyond December 31, 2026. However, there can be no assurance that further forbearance or a refinancing will be obtained on acceptable terms, or at all.

 

During the year ended March 31, 2026, the Company made a scheduled principal repayment of $600,000 under the Credit Agreement.

 

As of September 30, 2026, the outstanding balance under the Credit Agreement, including the exit fee of $1,425,000, was $15,270,932 (March 31, 2026 – $15,270,932). The related unamortized debt discount was $278,552 (March 31, 2026 – $590,018), resulting in a net carrying amount of $14,992,380 (March 31, 2026 – $14,680,914).

 

Debt discounts, including deferred financing costs, warrant-related discounts and other financing costs associated with the Credit Agreement, are amortized over the remaining term of the loan using the effective interest method.

For the three and six months ended September 30, 2026, the amortization of debt discount expense was $157,397 and $311,466 respectively. For the three and six months ended September 30, 2025, the amortization of debt discount expense was $190,495 and $344,067 respectively.

 

Total interest expense on the Credit Agreement for the three and six months ended September 30, 2026, amounted to $554,114 and $1,096,182, respectively. Total interest expense on the Credit Agreement for the three and six months ended September 30, 2025, amounted to $570,296 and $1,142,138, respectively

 

As of September 30, 2026 and September 30, 2025, accrued interest payable related to the Credit Agreement was $761,611 and $338,058, respectively.

 

27

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

7. FEDERALLY GUARANTEED LOAN

 

Economic Injury Disaster Loan (“EIDL”)

 

In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will.

 

In May 2021, the Company received an additional $499,900 from the SBA under the same terms.

 

As of September 30, 2026, the Company recorded accrued interest of $nil for the EIDL loan (March 31, 2026: $nil).

 

Interest expense on the above loan was $17,490 and $34,980 for the three and six months ended September 30, 2026, respectively, and $8,231 and $17,889 for the three and six months ended September 30, 2025, respectively.

 

8. DERIVATIVE LIABILITIES

 

The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the six months ended September 30, 2026 and March 31, 2026.

 

    September 30, 2026     March 31, 2026  
    $     $  
Derivative liabilities, beginning of period     1,396,908       1,478,717  
New issuance [Note 9]     —       -  
Change in fair value of derivatives during period     249,634       125,814  
Reduction due to preferred shares converted [Note 9]     (118,907 )     (207,623 )
Derivative liabilities, end of period     1,527,635       1,396,908  

 

The lattice methodology was used to value the derivative components of Preferred Stock, using the following assumptions during the six months ended September 30, 2026, and March 31, 2026:

 

   September 30, 2026   March 31, 2026 
Dividend yield (%)   12    12 
Risk-free rate for term (%)   3.5-4.5    3.5 – 4.1 
Volatility (%)   104.7-148.4    104.7 – 156.4 
Remaining terms (Years)   0.25-0.25    0.25 – 0.5 
Stock price ($ per share)   0.07-0.53    0.24 – 0.53 

 

28

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the six months ended September 30, 2026, and March 31 2026:

 

   September 30, 2026   March 31, 2026 
   $   $ 
Balance beginning of period   445,893    424,200 
Issuance   —    - 
Conversion to common shares   —    - 
Convertible note redemption   —    (19,842)
Change in fair value of derivative liabilities   11,877    41,535 
End of derivative treatment   —    - 
Balance end of period –   457,770    445,893 

 

The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended September 30, 2026 and March 31, 2026, using the following assumptions:

 

    September 30, 2026    March 31, 2026 
Risk-free rate for term (%)   0.2-4.5    0.2 – 4.1 
Volatility (%)   104.7- 148.4    104.7 – 172.5 
Remaining terms (Years)   0.25-0.47    0.25 – 0.47 
Stock price ($ per share)   0.07-0.71    0.24 – 0.71 

 

9. STOCKHOLDERS’ DEFICIENCY

 

(a) Authorized and Issued Stock

 

As at September 30, 2026, the Company is authorized to issue 125,000,000 (March 31, 2026 – 125,000,000) shares of common stock ($0.001 par value), and 10,000,000 (March 31, 2026 – 10,000,000) shares of preferred stock ($0.001 par value), 20,000 of which (March 31, 2026 – 20,000) are designated shares of Series A preferred stock, 600 of which (March 31, 2026 – 600) are designated shares of Series B preferred stock, and 2,100,000 of which (March 31, 2026 – nil) are designated shares of Series C preferred stock.

 

At September 30, 2026, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding totaled 21,792,165 (March 31, 2026 – 28,757,987) shares; these were comprised of 21,631,493 (March 31, 2026 – 28,597,315) shares of common stock and 160,672 (March 31, 2026 – 160,672) of exchangeable shares. At September 30, 2026, there were 201 shares of Series A Preferred Stock issued and outstanding (March 31, 2026 – 201), 310 shares of Series B Preferred Stock issued and outstanding (March 31, 2026 – 335), and 2,009,197 shares of Series C Preferred Stock issued and issuable (March 31, 2026 – nil), in connection with the exchange described in Note 9 (d), of which 494,231 shares remained to be issued as at September 30, 2026, pending completion of registration formalities with the Company’s transfer agent. There is also one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the Trust Agreement and outstanding as at September 30, 2026 and March 31, 2026.

 

29

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

(b) Series A Preferred Stock

 

The number of Series A Preferred Stock issued and outstanding as of September 30, 2026, and 2025 was 201 and 201, respectively.

 

The Series A Preferred Stock is junior to the Company’s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price for the Series A Preferred Stock to date has been $10,000 per share. Except as otherwise expressly required by law, the Series A Preferred Stock does not have voting rights and does not have any liquidation rights.

 

Preferred Stock Dividends

 

Dividends shall be paid at the rate of 12% per annum of the amount of the Series A Preferred stockholder’s purchase price. Dividends shall be paid quarterly unless the holder and the Company mutually agree to accrue and defer any such dividend.

 

Conversion

 

The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock; on a monthly basis, up to 5% of the aggregate amount of the purchase price can be converted (subject to adjustment for changes in the holder’s ownership of the underlying Series A Preferred Stock) subsequent to that issuance anniversary. The conversion price is equal to the greater of $0.001 or a 15% discount to the volume-weighted average price (“VWAP”) of the Company’s common stock five trading days immediately prior to the conversion date (the “Conversion Rate). Additionally, subject to certain provisions, the holder may exchange its Series A Preferred Stock into any common stock financing being conducted by the Company at a 15% discount to the pricing of that financing.

 

Other Adjustments and Rights

 

  ● The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization.
     
  ● The holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Company’s common stock on an as converted basis.

 

Company Redemption

 

The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate purchase price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110% plus accrued dividends.

 

(c) Series B Preferred Stock and Mezzanine Equity

 

On September 19, 2023, the Company entered into a Securities Purchase Agreement with an institutional investor for the issuance of Series B Convertible Preferred Stock (the “Series B Preferred Stock”). Each share of Series B Preferred Stock has a stated value of $10,000. During the years ended March 31, 2025 and 2024, the Company issued an aggregate of 550 shares of Series B Preferred Stock and received net proceeds of approximately $4.6 million. No Series B Preferred Stock was issued during the year ended March 31, 2026.

 

30

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

The Series B Preferred Stock ranks senior to the Company’s common stock with respect to dividends, distributions and liquidation preferences. Holders are entitled to cumulative dividends at a rate of 8% per annum, payable in cash or common stock in accordance with the terms of the Certificate of Designations. The Series B Preferred Stock is convertible into shares of the Company’s common stock pursuant to the terms of the Certificate of Designations and is also subject to redemption provisions. The Company may redeem outstanding shares of Series B Preferred Stock at a price equal to 110% of the stated value plus accrued but unpaid dividends and other amounts due.

 

On April 1, 2024, the Company filed an Amended Certificate of Designations pursuant to which the Series B Preferred Stock became non-voting, except as otherwise required by law. All other material rights and preferences of the Series B Preferred Stock remained substantially unchanged.

 

The Company has determined that the Series B Preferred Stock should be classified as mezzanine equity in accordance with ASC 480, Distinguishing Liabilities from Equity. Certain embedded conversion and redemption features are accounted for separately as derivative liabilities and are remeasured to fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations.

 

During the three and six months ended September 30, 2026, 25 Series B preferred shares converted along with dividends accrued thereon were converted into 4,354,504 common shares, of which 1,500,000 shares were issued and 2,854,504 shares are to be issued as at September 30, 2026. In addition, during the six months ended September 30, 2026, the Company issued 805,619 common shares to complete the settlement of a Series B preferred share conversion that was initiated in November 2025. During the three and six months ended September 30, 2025, 25 Series B preferred shares and dividends accrued thereon were converted into 223,839 common shares.

 

Accrued dividends related to the Series B Preferred Stock, which are included within Accounts Payable and Accrued Liabilities in the accompanying consolidated balance sheets, were $1,026,101 and $876,256 as of September 30, 2026 and March 31, 2026, respectively.

 

As of September 30, 2026 and September 30, 2025, 310 and 360 shares of Series B Preferred Stock were outstanding, respectively.

 

The carrying value of the Series B Preferred Stock classified as mezzanine equity was $1,560,391 and $1,750,290 as of September 30, 2026 and 2025, respectively.

 

A roll-forward of activity is presented below for the six months ended September 30, 2026:

 

   September 30, 2026   March 31, 2026 
   $   $ 
Balance beginning of period –   1,714,476    2,000,290 
Net proceeds received pursuant to the issuance of preferred shares   —    - 
Recognition of derivative liabilities   —    - 
Redemption of convertible preferred shares   —    (114,326)
Conversion into common shares   (154,084)   (171,488)
Balance end of period   1,560,391    1,714,476 

 

(d) Series C Preferred Shares

 

On May 1, 2026, the Company issued 1,957,297 shares of Series C Preferred Stock in exchange for 14,144,325 shares of common stock, 3,992,427 stock options and 1,436,216 warrants held by certain investors, officers and directors of the Company. The securities surrendered in the exchange were cancelled.

 

31

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

On May 22, 2026, the Company issued an additional 51,900 shares of Series C Preferred Stock in exchange for 319,000 stock options and 200,000 warrants, based on the same ten-for-one exchange ratio. Accordingly, the Company issued an aggregate of 2,009,197 shares of Series C Preferred Stock in connection with the exchanges during the six months ended September 30, 2026.

 

The Company designated 2,100,000 shares as Series C Preferred Stock, with a stated value of $2.35 per share. Each share carries 40 votes and has liquidation preference over the Company’s common stock but is subordinate to the Company’s Series B Preferred Stock.

 

The Series C Preferred Stock was valued using a probability-weighted expected return method (PWERM), incorporating the potential Qualified Financing, Fundamental Transaction, liquidation and March 31, 2028 conversion scenarios. The stock options and warrants were valued using the Black-Scholes model, and the common stock was valued using quoted market prices.

 

The Series C Preferred Stock automatically converts upon the completion of a qualified equity financing resulting in gross proceeds of at least $15 million. Upon such conversion, the Series C Preferred Stock will convert into common shares representing 59.6% of the Company’s outstanding common shares, after giving effect to shares issued or issuable in connection with the financing. If a qualified financing has not occurred by March 31, 2028, each Series C Preferred share becomes convertible, at the holder’s option, into ten common shares, subject to customary adjustments.

 

The Company accounted for the issuance of the Series C Preferred Stock and the surrender of the related common shares, stock options and warrants as an equity transaction. Accordingly, the transaction was recorded within stockholders’ equity and no gain or loss was recognized in the condensed consolidated statements of operations.

 

(e) Share issuances

 

Share issuances during the six months ended September 30, 2026

 

During the six months ended September 30, 2026, the Company issued a total of 2,305,619 common shares to Series B preferred shareholders. Of these, 805,619 common shares were issued in connection with Series B preferred share conversion that was initiated in November 2025 and recognized during the year ended March 31, 2026. The remaining 1,500,000 common shares were issued in connection with a new conversion notice received in August 2026 for 25 Series B preferred shares, together with dividends accrued thereon.

 

During the three months ended September 30, 2026, the Company issued 56,818 common shares for services received with a fair value of $6,136, which was recognized as a general and administrative expense with a corresponding credit to additional paid-in capital.

 

Share issuances during the six months ended September 30, 2025

 

During the six months ended September 30, 2025, the Company issued 223,839 common shares to Series B preferred shareholders, in relation to shares to be issued obligation as of March 2024 for Series B preferred share conversions.

 

(f) Shares to be issued

 

During the three months ended September 30, 2026, 2,854,504 common shares relating to the conversion of 25 Series B preferred shares, together with dividends accrued thereon, were recorded as shares to be issued and remain to be issued as at September 30, 2026.

In connection with the Series C Preferred Stock exchange described above, 4,816,066 shares of common stock included in shares to be issued are subject to cancellation pursuant to the exchange agreement. As of September 30, 2026, the cancellation of these shares had not yet been completed. Accordingly, the shares remain classified as shares to be issued pending completion of the cancellation process.

 

Activity during the six months ended September 30, 2025

 

None.

 

32

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

(g) Warrant issuances, exercises and other activity

 

Warrant exercises and issuances during the six months ended September 30, 2026

 

During the six months ended September 30, 2026, 1,436,216 warrants were exchanged for shares of Series C Preferred Stock in connection with the exchange described in Note 9(d).

 

Additionally, on May 22, 2026, the Company issued 200,000 warrants to an officer of the Company under the Company’s 2023 Equity Incentive Plan, with an exercise price of $0.12. These warrants were immediately exchanged for shares of Series C Preferred Stock in connection with the same exchange. The Company recorded stock-based compensation of $34,435 under selling, general and administrative expenses with a corresponding credit to additional paid-in capital.

 

During the six months ended September 30, 2026, the Company identified and corrected an immaterial 2,778 unit difference in previously reported Consultant and Noteholder Warrants outstanding.

 

No warrants were exercised for cash during the six months ended September 30, 2026.

 

Warrant exercises and issuances during the six months ended September 30, 2025

 

None.

 

Warrant activity during the six months ended September 30, 2026, is indicated below:

 

   Broker Warrants  

Consultant and

Noteholder Warrants

   Warrants Issued on Convertible Notes   Total 
As at March 31, 2026   956,077    1,438,994    868,098    3,263,169 
                     
Warrant issuance during the period   -    200,000    -    

200,000

 
Warrants exchanged for Series C Preferred Stock (Note9(d)        (1,636,216)        

(1,636,216

)
Adjustment to reconcile warrant balance        (2,778)        

(2,778

)
As at September 30, 2026   956,077    —    868,098    1,824,175 
                     
                     
Exercise Price   $0.37 to $37.56        $4.18      
Expiration Date   August 2026 to October 2033         October 2027      

 

(h) Stock-based compensation

 

2016 Equity Incentive Plan

 

On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.

 

33

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan is 1,241,422 shares; provided that the maximum number of shares of stock that may be issued under the Plan increases on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

 

2023 Equity Incentive Plan and the Employee Stock Purchase Plans

 

On March 31, 2023, the Company adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan authorizes grants of equity-based and incentive cash awards to eligible participants designated by the 2023 Plan’s administrator. The 2023 Plan will be administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). An aggregate of 5,000,000 shares of the Company’s common stock, plus the number of shares available for issuance under the Company’s 2016 Equity Incentive Plan that had not been made subject to outstanding awards, were reserved for issuance under the 2023 Plan. Unless earlier terminated by the Board, the 2023 Plan will remain in effect until all common stock reserved for issuance has been issued, provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date of the 2023 Plan.

 

The Company also adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP allows eligible employees of the Company and the Company’s designated subsidiaries the ability to purchase shares of the Company’s common stock at a discount, subject to various limitations. Under the ESPP, employees will be granted the right to purchase common stock at a discount during a series of successive offerings, the duration and timing of which will be determined by the ESPP administrator. In no event can any single offering period be longer than 27 months. The purchase price for each offering will be established by the administrator. With respect to an offering under Section 423 of the Internal Revenue Code of 1986 (“Section 423 Offering”), in no case may such purchase price be less than the lesser of (i) an amount equal to 85% of the fair market value on the commencement date, or (ii) an amount not less than 85% of the fair market value the on the purchase date. In the event of financial hardship, an employee may withdraw from the ESPP by providing a request at least 20 business days before the end of the offering period. Otherwise, the employee will be deemed to have exercised the purchase right in full as of such exercise date. Upon exercise, the employee will purchase the number of whole shares that the participant’s accumulated payroll deductions will buy at the purchase price. If an employee wants to decrease the rate of contribution, the employee must make a request at least 20 business days before the end of an offering period (or such earlier date as determined by the administrator). An employee may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participant’s lifetime, purchase rights under the ESPP shall be exercisable only by the participant.

 

During the six months ended September 30, 2026, options to purchase, 3,992,427 shares of common stock, held by certain officers and directors, were exchanged for shares of Series C Preferred Stock in connection with the exchange described in Note 9(d). The Company recorded stock-based compensation of $277,075 under selling, general and administrative expenses with a corresponding credit to additional paid-in capital, reflecting acceleration of previously unrecognized compensation cost for unvested awards of $130,115 and incremental fair value on modification of $146,960.

 

Additionally, on May 22, 2026, the Company granted 319,000 stock options under the 2023 Equity Incentive Plan at an exercise price of $0.12, which vested immediately and were immediately exchanged for shares of Series C Preferred Stock in connection with the same exchange. The Company recorded stock-based compensation of $28,460 under selling, general and administrative expenses with a corresponding credit to additional paid-in capital.

 

34

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

As of September 30, 2026, options outstanding were nil.

 

10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS

 

The Company has one operating lease primarily for office and administration.

 

During December 2021, the Company entered into a new lease agreement. The Company paid an $85,000 deposit that would be returned at the end of the lease. In December 2022, the Company started a new lease with an additional suite in the same premise as the existing lease.

 

The Company’s existing operating lease is nearing the end of its contractual term. As of September 30, 2026, the Company was in negotiations for a new lease arrangement for its office and administrative facilities. The terms of the proposed lease have not been finalized, and no definitive lease agreement has been executed. Accordingly, no right-of-use asset or lease liability related to a new lease arrangement has been recognized as of September 30, 2026.

 

When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4%.

 

   September 30, 2026   March 31, 2026 
Right of Use Asset  $   $ 
Beginning balance   346,214    812,053 
Amortization   (256,811)   (465,839)
Ending balance   89,403    346,214 

 

   September 30, 2026   March 31, 2026 
Lease Liability  $   $ 
Beginning balance   397,830    929,116 
Repayment and interest accretion, net   (295,523)   (531,286)
Ending balance   102,307    397,830 

 

   September 30, 2026   March 31, 2026 
Lease Liability  $   $ 
Current portion of operating lease liability   102,307    397,830 
Noncurrent portion of operating lease liability   —    — 

 

The operating lease expense was $292,676 for the six months ended September 30, 2026 (2025: $310,059) and included in the selling, general and administrative expenses. Operating cash flows from operating leases amounted to $308,377 and $299,396 during the six months ended September 30, 2026, and September 30, 2025, respectively.

 

The following table represents the contractual undiscounted cash flows for lease obligations as at September 30, 2026:

 

Calendar year  $ 
2026   102,793 
2027 and beyond   - 
Total undiscounted lease liability   102,793 
Less: imputed interest   486 
Total   102,307 

 

35

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (Unaudited)

(Expressed in US dollars)

 

11. COMMITMENTS AND CONTINGENCIES

 

There are no claims against the Company that were assessed as significant, which were outstanding as at September 30, 2026 or March 31, 2026 and, consequently, no provision for such has been recognized in the condensed consolidated interim financial statements.

 

12. PROPERTY AND EQUIPMENT

 

During the year-ended March 31, 2022, the Company purchased leasehold improvements of $12,928 (useful life: 5 years) as well as furniture & fixtures of $16,839 (useful life: 5 years). There were nil and no purchases of property and equipment during the six months ended September 30, 2026, and September 30, 2025. The Company recognized depreciation expense for these assets of $2,977 and $2,977, respectively, during the six months ended September 30, 2026, and 2025.

 

Cost  Office equipment   Leasehold improvement   Total 
   $   $   $ 
Balance at March 31, 2025   16,839    12,928    29,767 
Additions   —    —    — 
Balance at March 31, 2026   16,839    12,928    29,767 
Additions   —    —    — 
Balance at September 30, 2026   16,839    12,928    29,767 

 

Accumulated depreciation  Office equipment   Leasehold improvement   Total 
   $   $   $ 
Balance at March 31, 2025   11,409    8,759    20,168 
Additions   3,367    2,586    5,953 
Balance at March 31, 2026   14,776    11,345    26,121 
Depreciation for the period   1,687    1,289    2,977 
Disposals   —    —    — 
Additions   —    —    — 
Balance at September 30, 2026   16,463    12,634    29,098 
                
Net book value               
Balance at March 31, 2026   2,063    1,583    3,646 
Balance at September 30, 2026   375    294    669 

 

13. SUBSEQUENT EVENTS

 

During October 2026, the Company received confirmation that it was selected to provide cardiac screenings to patients in low-income communities and developing countries. Under the program, the Company will provide its remote cardiac monitoring technology and related services for patient screenings. The program is funded by charitable donations, and the Company will be paid in advance at rates consistent with its standard commercial pricing. The Company currently expects the program to involve the deployment of at least 1,000 devices. Any amounts received in advance will be recorded as deferred revenue and recognized when the related performance obligations are satisfied under ASC 606. There can be no assurance as to the timing or extent of device deployment, or the amount of revenue the Company will ultimately recognize under the program.

 

36

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Cautionary Note Regarding Forward-Looking Statements

 

Except for historical information contained herein, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: (a) any fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; (f) competition in the Company’s existing and potential future product lines of business; (g) the Company’s ability to obtain financing on acceptable terms if and when needed; (h) uncertainty as to the Company’s future profitability; (i) uncertainty as to the future profitability of acquired businesses or product lines; and (j) uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements, except as may be required under applicable law. Past results are no guaranty of future performance. Any such forward-looking statements speak only as of the dates they are made. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “plans,” “intends,” “will” and similar expressions are intended to identify forward-looking statements.

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and footnotes thereto included in this Quarterly Report on Form 10-Q (the “Financial Statements”).

 

Company Overview

 

Biotricity Inc. (the “Company”, “Biotricity”, “we”, “us”, “our”) is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. We believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue. In post-diagnostic markets, we intend to apply medical grade biometrics to enable consumers to self-manage, thereby driving patient compliance and reducing healthcare costs. We intend to first focus on a segment of the diagnostic mobile cardiac telemetry market, otherwise known as COM, while providing our chosen markets with the capability to also perform other cardiac studies.

 

We developed our Bioflux® (“Bioflux”) COM technology, which has received clearance from the U.S. Food and Drug Administration (“FDA”), comprised of a monitoring device and software components, which we made available to the market under limited release on April 6, 2018, to assess, establish and develop sales processes and market dynamics. Full market release of the Bioflux device for commercialization occurred in April 2019. The fiscal year ended March 31, 2021 marked our first year of expanded commercialization efforts, focused on sales growth and expansion. In 2021, we commenced the initial launch of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. In addition to developing and receiving regulatory approval or clearance of other technologies that enhance our ecosystem, in 2022, we launched our Biocore Cardiac Monitoring Device (“Biocore”, previously branded as Biotres), a three-lead device for ECG and arrhythmia monitoring intended for lower risk patients, a much broader addressable market segment. We have since expanded our sales efforts to 35 states, and intend to expand further and compete in the broader US market using an insourcing business model. Our technology has a large potential total addressable market, which can include hospitals, clinics and physicians’ offices, as well as other Independent Diagnostic Testing Facilities (“IDTFs)”. We believe our technological and clinical advantage combined with our insourcing model, which empowers physicians with state-of-the-art technology and charges technology service fees for its use, has the benefit of a reduced operating overhead for us, and enables a more efficient market penetration and distribution strategy.

 

37

 

 

We are a technology company focused on earning utilization-based recurring technology fee revenue. The Company’s ability to grow this type of revenue is predicated on the size and quality of its sales force and their ability to penetrate the market and place devices with clinically focused, repeat users of its cardiac study technology. The Company plans to grow its sales force to address new markets and achieve sales penetration in the markets currently served.

 

Full market release of the Bioflux COM device for commercialization launched in April 2019, after receiving its second and final required FDA clearance. To commence commercialization, we ordered device inventory from our FDA-approved manufacturer and hired a small, captive sales force, with deep experience in cardiac technology sales; we expanded on our limited market release, which identified potential anchor clients who could be early adopters of our technology. We then expanded our sales force and geographic footprint.

 

In 2021, we received a 510(k) clearance from the FDA for our Bioflux Software II System, engineered to improve workflows and reduce estimated review time from 5 minutes to 30 seconds. This improvement in review time reduces operational costs and allows us to continue to focus on excellent customer service and industry-leading response times to physicians and their at-risk patients. Additionally, these advances mean we can focus our resources on high-level operations and sales.

 

During 2021 and the early part of 2022, we also commercially launched our Bioheart technology, which is a consumer technology whose development was forged from the prior development of the clinical technologies that are already part of our technology ecosystem, the Biosphere. In recognition of our product development, in November 2022, Bioheart received recognition as one of TIME’s Best Inventions of 2022.

 

The COVID-19 pandemic highlighted the importance of telemedicine and remote patient monitoring technologies. We continue to develop a telemedicine platform, with capabilities of real-time streaming of medical devices. Telemedicine offers patients the ability to communicate directly with their health care providers without the need of leaving their home. Telemedicine aligns with our technology platform and facilitates remote visits and remote prescriptions for cardiac diagnostics; it can also serve as a means of establishing referral and other synergies across the network of doctors and patients that use the technologies we are building within the Biotricity ecosystem. We intend to continue to provide improved care to patients that may otherwise elect not to go to medical facilities and continue to provide economic benefits and cost savings to healthcare service providers and payers that reimburse. Our goal is to position ourselves as an all-in-one cardiac diagnostic and disease management solution. We continue to grow our data set of billions of patient heartbeats, allowing us to further develop our predictive capabilities relative to atrial fibrillation and arrythmias.

 

In January 2022, we received the 510(k) FDA clearance of our Biocore (previously named Biotres) patch solution, which is a novel product in the field of Holter monitoring. This three-lead technology can provide connected Holter monitoring that is designed to produce more accurate arrythmia detection than is typical of competing remote patient monitoring solutions. It is also foundational, since already developed improvements to this technology will follow which are not known by us to be currently available in the market, for clinical and consumer patch solution applications. In October 2023, we launched the cellular version of this device, the Biocore Pro.

 

In October 2022, we launched Biocare, after successfully piloting this technology in two facilities that provide cardiac care to more than 60,000 patients. This technology and other consumer technologies and applications such as the Biokit and Biocare have been developed to allow us to transform and use our strong cardiac footprint to expand into remote chronic care management solutions that will be part of the Biosphere. The technology puts actionable data into the hands of physicians to assist them in making effective treatment decisions quickly. During March 2023, we launched our patient-facing Biocare app on Android and Apple app stores. This further allows us to expand our footprint in providing full-cycle chronic care management solutions to our clinic and patient network. In January 2024, we appointed Dr. Fareeha Siddiqui, a scientist and expert in community health and diagnostics, to the position of VP of Healthcare to spearhead the roll-out and Biocare adoption to existing and new customers.

 

38

 

 

We are also developing several other ancillary technologies, which will require further FDA clearances, which we anticipate applying for within the next twelve months. Among these are:

 

  ● advanced ECG algorithms and analysis software for further improvements in sensitivity and specificity to analyze and synthesize patient ECG monitoring data with the purpose of distilling it down to the important information that requires clinical intervention, while reducing the amount of human intervention necessary in the process;
     
  ● the Biocore® 2.0, which is the next generation of our award winning Biocore®

 

We identified the importance of recent developments in accelerating our path to profitability, including the launch of important new products identified, which have a ready market through cross-selling to existing large customer clinics, and large new distribution partnerships that allow us to sell into large hospital networks.

 

Additionally, in September 2022, we were awarded a NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring, and predictive analytics for stroke due to chronic kidney failure. This is a significant achievement that broadens our technology platform’s disease space demographic. The grant focuses on Bioflux-AI as an innovative system for real-time monitoring and prediction of stroke episodes in chronic kidney disease patients. We received $238,703 under this award in March 2023, which we used to defray research and development and other associated costs.

 

Our mission is to innovate and create transformative healthcare products while ensuring financial discipline, to drive margin and revenue growth to deliver value creation for our investors. Our commitment to innovation means that we harness data intelligently to explore novel avenues for enhancing healthcare outcomes.

 

Through our Bioflux and Biocore products, Biotricity has monitored well over 160 billion heartbeats for atrial fibrillation (afib), a leading cause of strokes. Over the past two years, these efforts have benefited over 40,000 patients diagnosed with afib, by providing them with the prospect of earlier medical intervention – which also produces significant healthcare savings to patients and the healthcare system.

 

We are expanding our AI technology development in remote cardiac care, leveraging proprietary AI technology to provide a suite of predictive monitoring tools to enhance new disease profiling, improve patient management, and transform the healthcare industry for disease prevention.

 

We have also strengthened relationships with Amazon and Google. The healthcare AI market opportunity is projected to grow to $208.2 billion by 2030 according to Grand View Research. We have established a strong foothold, having built a powerful proprietary cardiac AI model that combines Google’s TensorFlow, AWS infrastructure, big data and a continuous learning engine. This combination allows us to rapidly improve our cardiac technology. In the near future, we believe the capabilities of our cardiac AI model will allow us to support healthcare professionals in handling exponentially more patients while identifying the most critical data. This will enable healthcare workers to elevate the quality of care while serving a larger number of patients. As growing patient numbers further stress the shortage of healthcare professionals, our technology could help alleviate this pressing issue. We have engineered our technology to not only improve patient care and outcomes, but to do so in a manner that supports more patients. This has led to increasing sales of our remote cardiac monitoring devices and the ramp-up of our subscription-based service, increasing our recurring revenue over the past few quarters.

 

Increasing interest and demand continue to drive the adoption of our suite of products, which are focused on chronic cardiac disease prevention and management. Our efforts in commercialization and development have yielded significant progress in remote monitoring solutions for diagnostic and post-diagnostic products.

 

39

 

 

Results of Operations

 

Quarterly operating results

 

Three-month periods; amounts in US$ thousands, except percentages.

 

Metric  Q2
FY27
   Q1
FY27
   Q4
FY26
   Q3
FY26
   Q2
FY26
   Q1
FY26
   Q4
FY25
   Q3
FY25
 
Revenue ($000)   4,334    4,277    4,251    3,988    3,886    3,874    3,703    3,619 
Gross profit ($000)   3,609    3,531    3,399    3,251    3,181    3,117    2,978    2,764 
Gross profit margin   83.3%   82.6%   80.0%   81.5%   81.9%   80.5%   80.4%   76.4%
SG&A ($000)   2,385    2,699    1,863    2,187    2,305    2,139    3,261    2,382 
R&D ($000)   885    673    842    624    603    696    573    551 
Total operating expenses ($000)   3,270    3,372    2,705    2,811    2,908    2,835    3,834    2,933 
Operating Profit/(Loss) ($000)   339    159    694    440    273    282    (856)   (169)
Operating efficiency ratio   75.4%   78.8%   63.6%   70.5%   74.8%   73.2%   103.5%   81.0%

 

The Company’s eight-quarter financial results demonstrate a favorable trajectory in revenue generation and gross profitability. Revenue increased consistently throughout the period, while gross profit margins expanded, indicating an improvement in the relationship between revenue and the direct costs of generating that revenue.

 

The combination of higher revenue improved gross margins, and relatively stable operating expenses in recent quarters has strengthened the Company’s operating performance before consideration of financing costs and other non-operating items.

 

Management believes that continued revenue growth, preservation of gross profit margins, and disciplined management of operating expenses will remain important factors in the Company’s efforts to improve operating profitability.

 

The following table sets forth our results of operations for the six months ended September 30, 2026, and 2025.

 

   For the six months ended September 30, 
   2026   2025   Period to Period Change 
Revenue  $8,611,403   $7,759,788   $851,615 
Cost of revenue   1,471,869    1,461,490    10,379 
Gross profit   7,139,534    6,298,298    841,236 
Gross Margin   82.9%   81.2%   1.7%
                
Operating expenses:               
Selling, general and administrative   5,084,806    4,443,573    641,233 
Research and development   1,557,945    1,298,961    258,984 
Total operating expenses   6,642,751    5,742,534    900,217 
Profit (Loss) from operations   496,783    555,764    (58,981)
                
Interest expense   (1,705,834)   (1,710,673)   4,839 
Accretion and amortization expenses   (373,509)   (355,713)   (17,796)
Change in fair value of derivative liabilities   (261,511)   (33,971)   (227,540)
Gain (loss) upon convertible promissory note conversion and redemption   —    8,433    (8,433)
Other income   76,442    173,270    (96,828)
Net loss before income taxes   (1,767,629)   (1,362,890)   (404,739)
Income taxes   —    —    — 
Net loss before dividends  $(1,767,629)  $(1,362,890)  $(404,739)

 

Revenue for the six months ended September 30, 2026 grew 11.0% year over year to $8.6 million, driven by a 18.3% increase in recurring technology fee revenue, which more than offset a decline in device sales. Gross margin improved to 82.9% from 81.2% and gross profit increased 13.4% to $7.1 million. Operating expenses increased 15.7%, primarily attributable to a 14.4% increase in selling, general and administrative expenses, including $340 thousand of non-cash share-based compensation recognized in the first quarter (compared to $12 thousand in the prior-year period), and a 19.9% increase in research and development expenses. As the increase in operating expenses exceeded the increase in gross profit, operating income decreased 10.6% to $0.5 million from $0.6 million. Net loss before dividends widened to $1.8 million from $1.4 million in the prior-year period, primarily due to a $262 thousand loss on the change in fair value of derivative liabilities (compared to a $34 thousand loss in the prior-year period) and lower other income. Management believes the underlying trend — recurring revenue growth and margin expansion — supports its plan to achieve sustained operating profitability and positive cash flow, even as near-term results were affected by higher non-cash compensation expense. Overall operating margin was 5.8% for the six months ended September 30, 2026, compared to 7.2% in the corresponding prior year period.

 

Revenue and cost of revenue

 

Technology fee revenue increased to $8.1 million during the six months ended September 30, 2026, which is a 18.3% increase over the corresponding six-month period of the prior year. The majority of this revenue is recurring, and its growth can be attributed to strong customer retention that is supported by the quality of customer and cardiologist-friendly support services that emphasize accuracy of diagnostics and ease-of-use. Technology fees comprised 94.6% of total revenue for the six months ended September 30, 2026, compared to 88.7% in the prior-year period. Device sales were $0.5 million for the six months ended September 30, 2026, a decrease of approximately 46.9% from the prior-year period, and comprised 5.4% of total revenue.

 

Gross profit percentage was 82.9% for the six months ended September 30, 2026, compared to 81.2% in the corresponding prior year period. The increase in gross margin is a result of improved margin on technology fee revenue (86.2% compared to 81.8%) and a higher proportion of technology fee revenue in our revenue mix, partially offset by lower margin on device sales (25.4% compared to 76.0%).Given consistent gross margin on technology fees of approximately 86%, and efficiencies gained in using AI in data processing as well as an evolving revenue mix where we expect technology fees to comprise an increasing proportion of revenue, we anticipate continued improvement in overall blended gross margin over time.

 

40

 

 

Operating Expenses

 

Total operating expenses for the six months ended September 30, 2026, were $6.6 million compared to $5.7 million for the six months ended September 30, 2025, driven primarily by selling, general and administrative expenses, and increased research and development spending.

 

Selling, General and administrative expenses

 

Selling, general and administrative expenses for the six months ended September 30, 2026 were $5.1 million, compared to $4.4 million for the six months ended September 30, 2025, representing an increase of approximately 14.4%. The increase was primarily attributable to higher share-based compensation expense, which increased to approximately $340 thousand from approximately $12 thousand in the comparable prior-year period, as well as the reclassification of certain expenses from cost of sales to selling, general and administrative expenses.

 

Research and development expenses

 

For the six months ended September 30, 2026 we recorded research and development expenses of $1.6 million, compared to $1.3 million for the six months ended September 30, 2025. The research and development activity related to both existing and new products. The increase in research and development activity was primarily due to higher prototyping and regulatory testing costs associated with the development of new technologies for our ecosystem and product enhancements.

 

Interest Expense

 

Interest expense for the six months ended September 30, 2026 was $1.7 million, unchanged from the corresponding period in 2025, demonstrating consistency in the average outstanding debt balance during both reporting periods.

 

Accretion and amortization expenses

 

For the six months ended September 30, 2026 and 2025, accretion expense was approximately $0.37 million and 0.36 million in each period. The expense remained consistent year over year, primarily due to a comparable level of financing arrangements and related debt instruments outstanding during the respective periods.

 

Change in fair value of derivative liabilities

 

For the six months ended September 30, 2026 and 2025, we recognized a loss of $262 thousand versus a loss of $34 thousand, respectively, related to the change in fair value of derivative liabilities. The fair value changes were largely attributed to the underlying change in our mezzanine equity, convertible notes and equity fair value.

 

Gain (loss) upon convertible promissory notes conversion

 

During the six months ended September 30, 2026, the Company did not recognize any gain on the conversion of convertible notes, compared to a gain of approximately $8 thousand during the six months ended September 30, 2025. The decrease was primarily attributable to the absence of convertible note conversions during the current period, whereas certain convertible notes were converted during the comparable prior-year period.

 

Other income (expense)

 

Net other income for the six months ended September 30, 2026, was approximately $76 thousand, compared to $173 thousand for the six months ended September 30, 2025. Net other income primarily consisted of processing fees and late payment charges. The decrease was primarily attributable to lower processing fees and late payment charges recognized during the current period.

 

41

 

 

The following table sets forth our results of operations for the three months ended September 30, 2026, and 2025.

 

   For the three months ended September 30, 
   2026   2025   Period to Period Change 
Revenue  $4,334,447   $3,885,795   $448,652 
Cost of revenue   725,733    704,297    21,436 
Gross profit   3,608,714    3,181,498    427,216 
Gross Margin   83.3%   81.9%   1.4%
                
Operating expenses:               
Selling, general and administrative   2,385,498    2,304,881    80,617 
Research and development   884,501    602,798    281,703 
Total operating expenses   3,269,999    2,907,679    362,320 
Profit (Loss) from operations   338,715    273,819    64,896 
                
Interest expense   (854,081)   (860,419)   6,338 
Accretion and amortization expenses   (176,873)   (202,141)   25,268 
Change in fair value of derivative liabilities   (151,460)   (8,771)   (142,689)
Gain (loss) upon convertible promissory note conversion and redemption   —    —    — 
Other income   35,538    106,599    (71,061)
Net loss before income taxes   (808,161)   (690,913)   (117,248)
Income taxes   —    —    — 
Net loss before dividends  $(808,161)  $(690,913)  $(117,248)

 

Revenue for the three months ended September 30, 2026, grew 11.5% year over year to $4.3 million, driven by a 13.3% increase in recurring technology fee revenue, which more than offset a decline in device sales. Gross margin improved to 83.3% from 81.9%, and gross profit increased 13.4% to $3.6 million. Operating expenses increased 12.5%, primarily attributable to research and development expenses, which increased 46.7%, while selling, general and administrative expenses increased 3.5%. As the increase in gross profit exceeded the increase in operating expenses, operating income increased 23.7% to $339 thousand from $274 thousand. Net loss widened to $0.8 million from $0.7 million in the prior-year quarter, primarily due to a $151 thousand loss on the change in fair value of derivative liabilities, compared to a $9 thousand loss in the prior-year quarter. Management believes the underlying trend — recurring revenue growth and margin expansion — supports its plan to achieve sustained operating profitability and positive cash flow. Overall operating margin was 7.8% this quarter compared to 7.0% in the corresponding prior year period.

 

Revenue and cost of revenue

 

Technology fee revenue increased to $4.0 million during the three months ended September 30, 2026, which is a 13.3% increase over the corresponding three-month period of the prior year. The majority of this revenue is recurring, and its growth can be attributed to strong customer retention that is supported by the quality of customer and cardiologist-friendly support services that emphasize accuracy of diagnostics and ease-of-use. Technology fees comprised 91.8% of total revenue for the three months ended September 30, 2026, compared to 90.4% in the prior-year quarter. Device sales were $0.4 million for the three months ended September 30, 2026, a decrease of approximately 5.1% from the prior-year quarter, and comprised 8.2% of total revenue.

 

Gross profit percentage was 83.3% for the three months ended September 30, 2026, compared to 81.9% in the corresponding prior year quarter. The increase in gross margin is a result of improved margin on technology fee revenue (85.5% compared to 82.3%) and a higher proportion of technology fee revenue in our revenue mix, partially offset by lower margin on device sales (58.0% compared to 78.1%). Given gross margin on technology fees of approximately 86%, efficiencies gained in using AI in data processing, and an evolving revenue mix where we expect technology fees to comprise an increasing proportion of revenue, we anticipate continued improvement in overall blended gross margin over time

 

42

 

 

Operating Expenses

 

Total operating expenses for the three months ended September 30, 2026, were $3.3 million compared to $2.9 million for the three months ended September 30, 2025, an increase of $0.4 million, or 12.5%. The increase was driven primarily by higher research and development expenses of $0.3 million, reflecting the timing of development activities for new technologies and product enhancements, together with a modest increase in selling, general and administrative expenses of $0.1 million.

 

Selling, General and administrative expenses

 

Selling, general and administrative expenses for the three months ended September 30, 2026 were $2.4 million, compared to $2.3 million for the three months ended September 30, 2025, representing an increase of approximately 3.5%. The slight increase was primarily attributable to higher professional fees, contractor and cloud hosting costs, largely offset by lower payroll and employee benefit costs.

 

Research and development expenses

 

For the three months ended September 30, 2026 we recorded research and development expenses of $0.9 million, compared to $0.6 million for the three months ended September 30, 2025, an increase of approximately 47%. The research and development activity related to both existing and new products. The increase in research and development activity was primarily due to higher prototyping and regulatory testing costs associated with the development of new technologies for our ecosystem and product enhancements.

 

Interest Expense

 

Interest expense for the three months ended September 30, 2026 was $0.9 million, unchanged from the corresponding period in 2025, demonstrating consistency in the average outstanding debt balance during both reporting periods.

 

Accretion and amortization expenses

 

For the three months ended September 30, 2026 and 2025, accretion expense was approximately $0.18 million and $0.20 million in each period. The expense remained consistent year over year, primarily due to a comparable level of financing arrangements and related debt instruments outstanding during the respective periods.

 

Change in fair value of derivative liabilities

 

For the three months ended September 30, 2026 and 2025, we recognized a loss of $151 thousand versus a loss of $9 thousand, respectively, related to the change in fair value of derivative liabilities. The fair value changes were largely attributed to the underlying change in our mezzanine equity, convertible notes and equity fair value.

 

Gain (loss) upon convertible promissory notes conversion

 

During the three months ended September 30, 2026 and 2025, the Company did not recognize any gain or loss on the conversion or redemption of convertible promissory notes, as no convertible notes were converted or redeemed in either period.

 

Other income (expense)

 

Net other income for the three months ended September 30, 2026 was approximately $36 thousand, compared to $107 thousand for the three months ended September 30, 2025. Net other income primarily consisted of processing fees and late payment charges. The decrease was primarily attributable to lower processing fees and late payment charges recognized during the current period.

 

43

 

 

EBITDA and Adjusted EBITDA

 

Earnings before interest, taxes, depreciation and amortization expenses (EBITDA) and Adjusted EBITDA, which are presented below, are non-generally accepted accounting principles (non-GAAP) measures that we believe are useful to management, investors and other users of our financial information in evaluating operating profitability. EBITDA is calculated by adding back interest, taxes, depreciation and amortization expenses to net income.

 

The Company continued to report positive EBITDA, with EBITDA of approximately $315 thousand for the six months ended September 30, 2026, compared to approximately $706 thousand corresponding period of the prior year. The decrease in EBITDA was primarily attributable to share-based compensation of approximately $340 thousand for the six months ended September 30, 2026, principally related to the acceleration and modification of awards in connection with the Series C Preferred Stock exchange (compared to approximately $12 thousand in the corresponding prior-year period).

 

Adjusted EBITDA is calculated by excluding from EBITDA the effect of the following non-operational items: equity in earnings and losses of unconsolidated businesses and other income and expense, net. We believe that this measure is useful to management, investors and other users of our financial information in evaluating the effectiveness of our operations and underlying business trends in a manner that is consistent with management’s evaluation of business performance. Further, the exclusion of non-operational items enables comparability to prior period performance and trend analysis.

 

We provide non-GAAP financial information to enhance the understanding of Biotricity’s GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies.

 

EBITDA and Adjusted EBITDA

 

   Three months ended
September 30, 2026
   Three months ended
September 30, 2025
   Six months ended
September 30, 2026
   Six months ended
September 30, 2025
 
   $   $   $   $ 
Net loss attributable to common stockholders   (954,041)   (772,323)   (2,024,351)   (1,526,616)
Add:                    
Provision for income taxes   —    —    —    — 
Interest expense   854,081    860,419    1,705,834    1,710,673 
Accretion and amortization expenses   176,873    202,141    373,509    355,713 
Depreciation   1,488    1,488    2,977    2,977 
Preferred stock dividends (2)   145,880    81,410    256,722    163,726 
EBITDA   224,281    373,135    314,691    706,473 
                     
Add (Less)                    
Share based compensation (1)   —    6,001    339,970    11,936 
Other (income)/loss (3)   (35,538)   (106,599)   (76,442)   (173,270)
(Gain) loss upon convertible promissory notes conversion and redemption (3)   —    -    —    (8,433 
Fair value change on derivative liabilities (3)   151,460    8,771    261,511    33,971 
Adjusted EBITDA   340,203    281,308    839,729    570,677 

 

(1) Share based compensation is a non-cash item therefore is removed from our adjusted EBITDA analysis

(2) Preferred stock dividend payment is at Company’s discretion and therefore is removed from our EBITDA analysis

(3) These items relate to financing transactions and therefore do not reflect the Company’s core operating activities

 

44

 

 

Translation Adjustment

 

Translation adjustment was a loss of $2 thousand versus a loss of $27 thousand for the six months ended September 30, 2026 and 2025, respectively. This translation adjustment represents gains and losses that result from the translation of currency in the financial statements from our functional currency of Canadian dollars to the reporting currency in U.S. dollars over the course of the reporting period.

 

Liquidity and Capital Resources

 

Management has noted the existence of substantial doubt about our ability to continue as a going concern. Additionally, our independent registered public accounting firm included an explanatory paragraph in the report on our financial statements as of and for the years ended March 31, 2026 and 2025, noting the existence of substantial doubt about our ability to continue as a going concern. Management believes that our existing cash, together with anticipated near-term financings and the planned refinancing of our term loan, would, if completed, be sufficient to fund our operating expenses for at least twelve months from the date of this filing; however, these financings and the refinancing have not been finalized and there can be no assurance that they will be completed. Runway Growth Finance Corp., the agent and a lender under our term loan, has agreed to forbear from exercising its rights and remedies through December 31, 2026, subject to the terms of our forbearance agreement, and we expect to obtain further forbearance beyond that date pending the refinancing of the term loan. To continue to fund operations, we will need to secure additional funding through public or private equity or debt financings, through collaborations or partnerships with other companies or other sources. We may not be able to raise additional capital on terms acceptable to us, or at all. Any failure to raise capital when needed could compromise our ability to execute our business plan. If we are unable to raise additional funds, or if our anticipated operating results are not achieved, we may need to reduce expenditure to extend the time period that existing resources can fund our operations. If we are unable to obtain the necessary capital, it may have a material adverse effect on our operations and the development of our technology, or we may have to cease operations altogether.

 

The development and commercialization of our product offerings are subject to numerous uncertainties, and we could use our cash resources sooner than we expect. Additionally, the process of developing our products is costly, and the timing of progress can be subject to uncertainty; our ability to successfully transition to profitability may be dependent upon achieving further regulatory approvals and achieving a level of product sales adequate to support our cost structure. Though we are optimistic with respect to our revenue growth trajectory and our cost control initiatives, we cannot be certain that we will ever be profitable or generate positive cash flow from operating activities.

 

The Company is in commercialization mode, while continuing to pursue the development of its next generation COM product as well as new products.

 

We generally require cash to:

 

  ● purchase devices that will be placed in the field for pilot projects and to produce revenue,
     
  ● launch sales initiatives,
     
  ● fund our operations and working capital requirements,
     
  ● develop and execute our product development and market introduction plans,
     
  ● fund research and development efforts, and
     
  ● pay any expense obligations as they come due.

 

The Company is in the early stages of commercializing its products. It is concurrently in development mode, operating a research and development program in order to develop an ecosystem of medical technologies, and, where required or deemed advisable, obtain regulatory approvals for, and commercialize other proposed products. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and additional equity and debt capitalization of the Company. The Company has incurred recurring losses from operations, and as at September 30, 2026, has an accumulated deficit of $145 million (March 31, 2026: $143 million), and a working capital deficit of $32 million (March 31, 2026: $31 million).

 

45

 

 

On August 30, 2021 the Company completed an underwritten public offering of its common stock that concurrently facilitated its listing on the Nasdaq Capital Market. On August 1, 2024, the Company received a notice from Nasdaq stating that Nasdaq has determined to delist the Company’s shares of common stock on The Nasdaq Capital Market, effective at the open of business on August 5, 2024. Nasdaq reached its decision pursuant to Nasdaq Listing Rule 5550(b)(2) because the Company no longer complied with the minimum $35 million market value of listed securities. Following the suspension of trading on The Nasdaq Capital Market, the Company’s shares of common stock were again quoted on the OTCQB under the symbol “BTCY.”

 

During the six months ended September 30, 2026, the Company continued to fund its operations through a combination of debt financing arrangements and existing financing facilities.

 

As of September 30, 2026, the Company had cash and cash equivalents of $268,998 and continued to evaluate additional financing alternatives to support working capital requirements, product development initiatives and future growth opportunities.

 

During October 2026, the Company received confirmation that it was selected to provide cardiac screenings to patients in low-income communities and developing countries. Under the program, the Company will provide its remote cardiac monitoring technology and related services for patient screenings. The program is funded by charitable donations, and the Company will be paid in advance at rates consistent with its standard commercial pricing. The Company currently expects the program to involve the deployment of at least 1,000 devices. Any amounts received in advance will be recorded as deferred revenue and recognized when the related performance obligations are satisfied under ASC 606. There can be no assurance as to the timing or extent of device deployment, or the amount of revenue the Company will ultimately recognize under the program.

 

The Company has consistently reported positive Free Cash Flows for six previous quarters, which is defined as the operating cash flow generated by the Company that is available to pay for dividend and interest obligations. Free Cash Flow is a non-generally accepted accounting principle (“non-GAAP”) measure that represents the cash that the Company generates from its operations after deducting cash used on operating expenses and any capital asset spending. Unlike other accounting measures such as earnings or net income, this measure of profitability excludes non-cash expenses, but includes spending on capital assets and changes in working capital on the Company’s Balance Sheet. This is a key measure that management and investors use to evaluate progress towards Company profitability.

 

    6 months ended
September 30, 2026
    6 months ended
September 30, 2025
 
    $     $  
Net cash generated (used) in operating activities     510,748       42,241  
Add:                
Interest expense     1,705,834       1,710,673  
Less:                
Investment in capital assets     —       —  
Free Cash Flows     2,216,582       1,752,914  

 

The Company continues to pursue sources of funding, including the refinancing of its term loan, that management believes, if completed, would be sufficient to support the Company’s operating plan for at least one year from the date of these condensed consolidated interim financial statements. Until such financing is completed, substantial doubt about the Company’s ability to continue as a going concern remains.

 

As we proceed with the commercialization of the Biocore and Biocare products and continue their development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures.

 

Based on the above facts and assumptions, we believe that our existing cash, along with anticipated near-term financings and the planned refinancing of our term loan, if completed, would be sufficient to meet our needs for the next twelve months from the filing date of this report. However, these financings and the refinancing have not been finalized, and there can be no assurance that they will be completed on acceptable terms, or at all. We will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financing may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.

 

46

 

 

The following is a summary of cash flows for each of the periods set forth below.

 

   For the six Months Ended 
   September 30, 
   2026   2025 
Net cash generated (used) in operating activities  $510,748   $42,241 
Net cash used in investing activities   —    — 
Net cash provided by (used in) financing activities   (389,460)   (72,043)
Effect of foreign currency translation   (2,079)   (26,883)
Net Increase (decrease) in cash  $119,209   $(56,685)

 

Net Cash Generated (Used) in Operating Activities

 

During the six months ended September 30, 2026, we generated cash in operating activities of $511 thousand compared to $42 thousand cash generated for the corresponding prior year period. The cash in operating activities was primarily due to selling expenses as well as research, product development, business development, marketing and general operations. The increase in cash generation reflects management’s concerted effort to contain costs while increasing revenues.

 

Net Cash Used in Investing Activities

 

Net cash used in investing activities was Nil and Nil during the six months ended September 30, 2026 and 2025.

 

Net Cash Provided by (Used in) Financing Activities

 

Net cash used in financing activities was $389 thousand compared to net cash used of $72 thousand during the six months ended September 30, 2026 and 2025, respectively.

 

For the six months ended September 30, 2026, the net cash used by financing activities was primarily due to net repayments of short-term loans and promissory notes of $383 thousand and the payment of preferred stock dividends of $6 thousand.

 

For the six months ended September 30, 2025, the net cash used by financing activities was primarily due to the proceeds from convertible promissory notes and short-term loan of $0.7 million, which is offset by the payment of $0.6 million of term loan and redemption of preferred shares of $0.2 million.

 

Critical Accounting Estimates

 

Our consolidated interim financial statements are prepared in accordance with GAAP. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based upon information available to us at the time that we make these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our 2026 Form 10-K filed on July 14, 2026.

 

During the six months ended September 30, 2026, there were no material changes to our critical accounting estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2026 Form 10-K filed on July 14, 2026.

 

Recent Accounting Pronouncements

 

Refer to Note 3— Summary of Significant Accounting Policies to our condensed consolidated interim financial statements included elsewhere in this report for a discussion of recently issued accounting pronouncements.

 

47

 

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for a smaller reporting company.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of “disclosure controls and procedures” in Rule 13a-15(e). The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Company’s desired disclosure control objectives. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation.

 

At the end of the period being reported upon, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, as well as recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to the Company.

 

Changes in Internal Control

 

There were no changes in the Company’s internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

48

 

 

PART II

 

OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to, and our property is not the subject of, any material legal proceedings. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

Item 1A. Risk Factors

 

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the three months ended September 30, 2026, the Company issued the following equity securities that were not registered under the Securities Act of 1933, as amended (the “Securities Act”):

 

In August 2026, the Company received a notice of conversion of 25 shares of Series B Preferred Stock, together with dividends accrued thereon, into an aggregate of 4,354,504 shares of common stock, of which 1,500,000 shares were issued during the quarter and 2,854,504 shares remained to be issued as at September 30, 2026. These shares were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act, as they were issued in exchange for securities of the Company held by an existing security holder, and no commission or other remuneration was paid or given, directly or indirectly, for soliciting the exchange.

 

In September 2026, the Company issued 56,818 shares of common stock, with a fair value of $6,136, as consideration for services rendered. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving a public offering.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

During the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 6. Exhibits

 

31.1   Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1   Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2   Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101   Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

** Furnished herewith.

 

49

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 16th day of November 2026.

 

BIOTRICITY INC.

 

By: /s/ Waqaas Al-Siddiq  
Name: Waqaas Al-Siddiq  
Title: Chief Executive Officer  
  (principal executive officer)  
     
By: /s/ John Ayanoglou  
Name: John Ayanoglou  
Title: Chief Financial Officer  
  (principal financial and accounting officer)  

 

50

Keep reading